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Abstract 
 
Certain amino acids have a high propensity to be found at the intermolecular contact 
regions in protein-nucleic acid complexes. One of them is arginine whose side chain 
commonly makes contact through electrostatic interactions with phosphates and hydrogen 
bonding to nucleobases. Rigidified arginine analogues in which the side chain is cyclised 
would reduce torsional entropy loss occurring on binding. In this project amino acids were 
synthesised with cyclic guanidine side chains as modular arginine analogue building 
blocks for preparation of nucleic acid binding peptides. 
The synthetic strategies to prepare the amino acids involve Grignard reactions and Heck 
coupling reactions with iodo-pyrimidines. The Heck coupling is followed by a catalytic 
asymmetric hydrogenation to generate the stereo centre. An enzymatic kinetic resolution is 
essential after the Grignard coupling to provide stereoselectivity. 
Small molecule interactions with nucleic acids can be used as a tool for modulating 
processes like transcription and translation. Ultimately peptide binding screens against the 
mRNA of TGF-β1 may be undertaken to study the role of protein binding in regulation of 
translation. 
Within this thesis a peptide library was prepared via the split and recombine method using 
macro-beads which provides valuable groundwork for the aim of continuing research. This 
would be the synthesis of peptides containing rigidified arginine mimetics that interact 
with mRNA of TGF-β1 or other nucleic acids.  
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1. Introduction 
 
1.1 Amino acids 
 
Amino acids are a class of organic compounds that are important as protein building 
blocks. 
Most natural amino acids possess the amino group in the α-position, i.e. bound to the 
carbon atom adjacent to the carboxylic acid group. This α-carbon atom is a chiral centre in 
all twenty naturally occurring amino acids that are the base of all proteins (proteinogenic 
amino acids, Figure 3) with the exception of glycine. Two conventions are in use to 
describe the stereo chemistry of amino acids: the Fischer-projection and a three-
dimensional drawing (Figure 1). In the Fischer-projection all proteinogenic amino acids 
show the NH2-group on the left side, i.e. they have L-configuration. In accordance with 
the priorities as defined by Cahn, Ingold and Prelog nearly all amino acids are of S-
configuration with the exception of cysteine. The cysteine has per definition R-
configuration because the sulphur in the cysteine side chain has a higher priority than 
oxygen
[1]
 (Figure 2).  
 
H2N CO2H
RH
COOH
CH2N H
R
Fischer
projection
three-dimensional
configuration  
Figure 1: Common conventions to show the stereochemistry of amino acids. 
 
H2N
1
COOH
2
H2C
3 OH
H2N
1
COOH
3
H2C
2 SH
(S)-Serine (R)-Cysteine  
Figure 2: Serine and cysteine as examples of naturally occurring R and S amino acids. 
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H2N COOH H2N COOH H2N COOH H2N COOH H2N COOH
Glycine
(Gly, G)
Alanine
(Ala, A)
Valine
(Val, V)
Leucine
(Leu, L)
Isoleucine
(Ile, I)
H2N COOH
SH
H2N COOH
OH
H2N COOH
OH
H2N COOH
CONH2
H2N COOH
CONH2
Cysteine
(Cys, C)
Serine
(Ser, S)
Threonine
(Thr, T)
Asparagine
(Asn, N)
Glutamine
(Gln, Q)
Neutral Amino Acids
H2N COOH H2N COOH H2N COOH H2N COOH
OH
NH SCH3
N
H
COOH
Phenylalanine
(Phe, F)
Tyrosine
(Tyr, Y)
Tryptophan
(Trp, W)
Methionine
(Met, M)
Proline
(Pro, P)
Basic Amino Acids
Acidic Amino Acids
H2N COOH H2N COOH
H2N COOH
COOH
H2N COOH
NH2
H2N COOH
H
N
NH
NH2
N
NH
Lysine
(Lys, K)
Arginine
(Arg, R)
Histidine
(His, H)
COOH
Aspartic Acid
(Asp, D)
Glutamic Acid
(Glu, E)  
Figure 3: Proteinogenic amino acids distinguished into neutral amino acids, acidic amino acids and basic 
amino acids. 
Chapter 1     Introduction 
3 
 
Three groups of natural amino acids may be distinguished: neutral amino acids (one amino 
group and one carboxylic acid group), acidic amino acids (one amino and two carboxylic 
acid groups) and basic amino acids (one carboxylic acid and two basic functionalities). A 
three-letter-code is often used for simplification to describe amino acids or peptides (e.g. 
Arg for arginine). The considerably larger proteins can only be described in a practical 
manner with the one-letter-code (e.g. R for arginine). 
 
The twenty α-amino acids are a necessary requirement of the protein biosynthesis. Only 
twelve of these can be produced by the human body. The remaining eight are essential 
amino acids (leucine, isoleucine, valine, threonine, phenylalanine, tryptophan, methionine, 
lysine) that have to be absorbed from nutrition.
[2]
 In certain proteins further amino acids 
(Figure 4) do occur as for example hydroxyproline (Hyp, 1) which is a major component 
of the protein collagen. Here the hydroxyl group is introduced into the proline on the 
gamma carbon atom after the protein synthesis. This phenomenon is described as “post 
translational modification”.[3] Two further proteinogenic amino acids are selenocysteine 
(2) and pyrrolysine (3) which are ribosomally incorporated by transfer RNA with 
anticodon UCA or CUA, respectively. 
 
N
H
COOH
1
Hydroxyproline
(Hyp)
COOH
H2N
H2N COOH
HO
4
beta-Alanine
5
gamma-Amino Butyric Acid
CO2HH2N
SeH
2
Selenocysteine
(Sec)
CO2HH2N
N
H
O
N
3
Pyrrolysine
(Pyl)
 
Figure 4: Structures of hydroxyproline, selenocysteine, pyrrolysine, β-alanine and γ-amino butyric acid. 
 
Apart from the α-amino acids there are further biologically important amino acids which 
are described as β, γ, δ and ε amino acids depending on the position of the amino group. 
These compounds are not part of proteins but have biological functions as transmitters or 
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have a part in metabolism. For example β-alanine (4) is found in coenzyme A and γ-amino 
butyric acid (5) is an important neurotransmitter in the brain.
[3]
 
 
 
Ampholytic character of amino acids 
 
Amino acids present both, basic and acidic properties. Thus an intramolecular 
neutralisation is possible that leads to zwitterions (Figure 5). 
 
+H3N COO
-
RH
H2N COO
-
R
H
+H3N COOH
R
H
Anion CationZwitterion  
Figure 5: Structure of amino acid depends on pH-value. At isoelectric point (IEP) the amino acid occurs as a 
zwitterion, at pH-values larger than IEP as anion and at pH-values smaller than IEP as cation. 
 
In aqueous media the amino group can remove the hydrogen ion from the carboxylic 
group and the NH3
+
 group is then the acidic group of an amino acid. The pKA is describing 
the acidity of this group and the pKB is related to the basic effect of the carboxylate 
moiety. The isoelectric point (IEP) is the pH-value where the intramolecular neutralisation 
is complete. A compound occurs as anion if the pH-value is larger than the isoelectric 
point and as cation if the pH-value is smaller than the isoelectric point.
[3]
 
 
 
Isolation and Synthesis of Amino Acids 
 
The proteinogenic amino acids are mainly obtained by isolation from hydrolysed proteins. 
This procedure cannot be used to gain D-amino acids or unnatural amino acids. Therefore 
a number of synthetic methods have been developed.  
One important method is the Strecker synthesis (Scheme 1). An aldehyde reacts with 
ammonia and hydrogen cyanide to yield α-aminonitrile. Hydrolysis of the α-aminonitrile 
gives the final amino acid as racemic mixture.  
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R
H
O NH3 HCN
- H2O
H2N CN
RH
H2N COOH
RH+ 2 H2O
- NH3
alpha-
Aminonitrile
alpha-
Amino Acid  
Scheme 1: Strecker synthesis is one of the important methods to synthesise amino acids. 
 
Another important synthetic method is the amination of α-halogen carboxylic acids 
(Scheme 2). For example α-bromo carboxylic acid can be obtained by Hell-Volhard-
Zelinsky halogenation reaction and can then be reacted with an excess of ammonia. The 
excess is necessary because the amino group of the product amino acid is more 
nucleophilic than the ammonia and would also react with the α-bromo carboxylic acid.  
 
COOH Br2
phosphorus
(cat.)
COOH
Br
NH3
COOH
NH2
Hell-Vollhard-Zelinsky Reaction Alanine  
Scheme 2: Alanine synthesis by amination of α-halogen carboxylic acid. 
 
In the Gabriel synthesis this problem is resolved by using potassium phthalimide instead 
of ammonia (Scheme 3). Potassium phthalimide reacts with for example bromomalonic 
ester and the product is subsequently alkylated and then hydrolysed. Carbondioxide is set 
free by heating which yields the desired amino acid. 
 
N
O
O
K+ Br
COOR
COOR
- KBr
N
O
O
COOR
COOR
Potassium
Phthalimide
base
R'-Hal
N
O
O
COOR
COOR
R'
1) H3O
+
2) heat
COOH
COOH
H2N COOH
R'H
CO2 2 ROH
Bromomalonic
Ester
 
Scheme 3: Gabriel synthesis to prepare amino acids using potassium phthalimide and bromomalonic ester. 
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The disadvantage of all presented synthesis methods is that the amino acids are obtained 
as a racemate. In a racemic mixture the amino acid is present as 50/50 mixture of S- and R-
configuration. Separation of the racemate into the enantiomers can take place by certain 
methods. The three main methods are inoculation of a supersaturated racemic solution 
with one enantiomer (for racemate which crystallise as conglomerate – pure crystals of 
each enantiomer), transformation of one enantiomer by enzyme and preparation of 
diastereomers by reaction with another chiral compound.
[1]
 
Various methods described in the literature for the synthesis of enantiomeric pure 
compounds include an isomer separation during or at the end of the synthesis. 
Preparatively this is time consuming and expensive and it is also creates waste for disposal 
if just one isomer is of significance. Therefore it is of interest to synthetically eliminate 
unwanted optical isomers as early as possible during the preparation or make both isomers 
in pure form separately available.  
Asymmetric synthesis is the synthesis of optically active compounds from achiral 
precursors with the use of optically active catalysts or auxiliaries. That offers the 
possibility to prepare the isomer of interest of amino acids and unnatural amino acids. 
Unnatural amino acids are of particularly interest for drug development and drug 
optimisation. For example the generation of peptide derivatives with an increased 
bioavailability and activity is important for the application of peptide agents. Substitution 
of S amino acids for R amino acids results in inhibited proteolysis by proteinase because D 
amino acids are uncommon in nature. Modifications in the peptide side chains or in the 
peptide backbone also reduce the degeneration.  
 
 
 
1.2 Arginine Derivatives 
 
The 20 naturally occurring amino acids show different propensities to bind with nucleic 
acids. Protein-DNA and protein-RNA crystal structures show a very high frequency of 
hydrogen bonding, water mediated hydrogen bonding and van der Waals contacts of 
arginine to the nucleic acid.
[4]
 The arginine side chain, therefore, is an effective ligand for 
nucleic acids. 
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The guanidine group of arginine enables it to perform some specific functions in the 
organism. Strong ionic binding of the guanidine to carboxylates like aspartic acid ensures 
specificity at the active site of many target proteins. The concepts and approaches that 
have been introduced to chemically diversify arginine are numerous and versatile.
[5]
 
Therefore only some recent and typical or outstanding examples will be discussed here. 
Arginine is an important nitrogen reservoir. As such it participates in the urea cycle and it 
also is the exclusive precursor of physiological nitrogen oxide (NO). The biochemical 
functions of NO are manifold and new insights are being gained continuously. 
It is known that NO is an important vasodilatator and may provide protection from 
atherosclerotic events. It is also of importance in blood coagulation. Last but not least it is 
a potent neurotransmitter that influences functions such as memory and pain regulation. 
All these physiological processes have motivated researchers in recent years to undertake 
synthetic efforts in the field of arginine mimetics due to the many potential pharmaceutical 
applications. 
Nitric oxide synthases and arginases are the enzymes that regulate the NO level. A straight 
forward approach is to identify arginine mimetics that may inhibit selectively arginine 
sensitive receptors. Foremost the development of thrombin inhibitors has been a field of 
intensive and extensive work.
[6-10]
 
Already relatively small chemical alterations of arginine as they do occur in natural 
physiological processes may have significant impact on the binding affinity towards an 
enzyme. Protein-methyl-Transferases (PRMTs) methylate L-arginine to give N
ω
-
methylated L-arginines. These compounds are arginase inhibitors. The rate of the 
biosynthesis of these compounds therefore directly influences the plasma level of arginine 
and the concentration of NO. Patients that suffer of illnesses such as hypertension, renal 
disease, high cholesterol or diabetes mellitus do show increased levels of N-methylated 
arginines. An interesting project recently synthesised N
δ
-methyl-L-arginine (6, Figure 6) 
and determined its binding properties towards the enzymes that control the NO plasma 
level. It became apparent that this compound was only a weak inhibitor or in some cases 
even a poorly binding substrate. Although this compound had also been identified as a 
natural product previously the authors conclude that their results show that a physiological 
function in humans is highly unlikely.
[8]
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N ethyl-L-Arginine
6
 
Figure 6: Structure of Nδ-methyl-L-arginine. 
 
Substrates containing highly basic groups like guanidine are commonly poorly absorbed 
after oral administration. Hence the bioavailability of arginine mimetics is often far from 
ideal. A common strategy in the synthesis of arginine mimetics is therefore to reduce the 
basicity while maintaining or better even improving the binding selectivity. Not long ago 
an extensive library of arginine based thrombin inhibitors was introduced that showed 
very good selectivity.
[10]
 
Wang et al. showed that the introduction of a nitro group in the ω-position and alkyl 
esterification (7, Figure 7) improve inhibitory effects on nitric oxide synthase (NOS).
[9]
 
 
O
H
N
H
N
NO2
O
NH2
NH
N-Nitro-L-Arginine Propyl Ester
7
 
Figure 7: Structure of N
ω
-nitro-L-arginine propyl ester. 
 
Synthesis strategies to rigidify arginine are of foremost interest. Means to achieve this may 
be the introduction of double bonds or ring systems. It is generally agreed that a 
compound promises to be a more effective inhibitor or antagonist for energetic reasons if 
it possesses fewer degrees of rotational freedom than the natural substrate. Rigidification 
may also lead to a higher lipophilicity of the molecule and a higher stability towards 
metabolic enzymes. The latter reasons may both lead to higher bioavailability. It does not 
come as a surprise that many arginine mimetic synthesis projects appreciate this in their 
strategies.
[6, 10-12]
 
Enduracididine (8, Figure 8) is a rigid arginine derivative and a natural product, too. This 
compound shows interesting biologic activity. It is a component of the peptide antibiotic 
enduracidine as well as of the antibiotic minosaminomycin and was also identified in the 
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cytotoxic fraction of extracts of Leptoclinides dubius (a marine ascidian). Recently the 
stereoselective synthesis was published.
[11]
 
 
 
-O
O
NH3
+
N
NH
NH2
Enduracididine
8
 
Figure 8: Structure of enduracididine. 
 
C3a is an important peptide that functions as an anaphylotoxin in the complement system. 
It promotes inflammatory responses and increased levels of C3a have been related to 
chronic inflammatory disease such as asthma, rheumatoid arthritis and multiple sclerosis. 
The inhibition of the C3a receptor (C3aR) therefore seems to be a promising target and 
Denonne et al. have developed a potent candidate through rigidification of a known 
inhibitor by incorporating a furan moiety (9, Figure 9). However, according to the authors 
this compound still suffers of the lack absorption when administered orally which is down 
to the unaltered guanidine moiety.
[12]
 
 
O
N
HPh
Ph
CO2H
NH
NH2
HN
O
9  
Figure 9: Structure of small molecule ligand of C3a receptor. 
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1.3 Peptides/Proteins 
 
Amino acids can be polymerised and form chains. This process can be regarded as a 
condensation reaction (loss of a water molecule). The created CO-NH-linkage is an amide 
bond but is also commonly described as peptide bond (Figure 10). Depending on the 
number of linked amino acids these polymers are called di-, tri-, oligo- or polypeptides.  
 
+H3N
N C
O-
H
O
O
Dipeptide
(Ala-Leu)
Peptide Bond  
Figure 10: Peptide bond demonstrated as dipeptide Ala-Leu. 
 
Polypeptides are linear polymers and each amino acid takes part in two peptide bonds 
apart from the ones at the end of the chain. Peptide bonds are stabilised by mesomerism. 
This mesomerism induces the partial double bond character of the amide group and makes 
the peptide bond relatively rigid i.e. not freely rotatable (Figure 11). The partial double 
bond character is confirmed by the measured C-N bond length which is 132 pm in 
comparison to 147 pm of a normal C-N single bond.
[13]
 
 
C N
O
H
C N+
-O
H
C N
O
H
Mesomeric Structure
Contributing Structures
 
Figure 11: Peptide bonds are stabilised by mesomerism which explains the partial double bond character.[13] 
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The side chains of the amino acids hinder each other less in the trans conformation in 
which the hydrogen of the substituted amino group is in trans position to the oxygen of the 
carbonyl group (Figure 12). Therefore the trans conformation is in general more stable 
than the cis conformation.
[13]
 
 
C N
O
R H
R
C N
O
R R
H
trans cis  
Figure 12: Trans and cis conformation of the peptide bond.  
 
The peptide backbone is formed by recurring NH-CO-CHR groups with rigid and planar 
peptide units. The order of the amino acids in the peptide is also called the sequence or 
primary structure. 
Secondary structure accrues by folding from the primary structure and occurs in three 
forms: α-helix, β-sheet and turns. In the case of L amino acids the α-helix is right-handed 
and is stabilised by intramolecular hydrogen bonds between every (i +4)th amino acid. 
The amino acid side chains are directed outwards. β-Sheets are stabilised mainly through 
hydrogen bonds between neighbouring peptide strands and hydrophobic interactions 
between side chains on the same face of the sheet. The peptide strands can be organised in 
parallel or antiparallel alignment and the peptide level resembles a folded sheet. The 
amino acid side chains point out of the plane.
[3]
 The tertiary structure of a protein 
describes its overall layout which depends on the configuration of the secondary structure 
units. Disulfide bonds, salt bridges, hydrogen bonds and hydrophobic interactions are 
involved in the stabilisation of the tertiary structure. A quatenary structure is formed when 
several protein subunits form one protein complex. 
 
The proteins are complex structures from folded polypeptide chains which can be several 
thousand amino acids long. They play an important role in all bioprocesses and have very 
different applications like as structural proteins (collagen in cartilages, bones and sinews, 
elastin for elasticity in arteries, keratin in hair and nails), contractile proteins (actin and 
myosin in muscles), transport proteins (haemoglobin for O2 transport, transferrin for Fe 
transport), regulatory proteins (insulin for regulation of blood glucose level, parathormone 
for regulation of Ca
2+
 and PO4
3−
 level in the blood), catalytic proteins (enzymes like 
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oxidoreductase, transferase, hydrolase) and they regulate important functions in gene 
expression like transcription and translation.
[14]
 
 
 
Branched Peptides 
 
Branched peptides are not just a product of synthetic chemistry they are also part of 
biochemical processes. The protein ubiquitin (76 amino acids) for example binds to other 
proteins and tags them for degradation. Ubiquitin binds towards other proteins with the 
amino acid glycine (G76) and forms an amide bond with a lysine side chain of the target 
protein. It also contains seven lysines which enable the binding of additional ubiquitins. 
Another example for naturally occurring branched peptides is peptidoglycan. 
Peptidoglycan is formed of cross-linked peptide chains of identical peptidoglycan 
monomers (NAG-NAM-pentapeptide). The monomer consists of two joined amino sugars 
NAG (N-acetylglucosamine) and NAM (N-acetylmuramic acid) with a pentapeptide linked 
to the NAM. The precise structure of the pentapeptide varies with bacterial species and the 
branching can occur through lysine. The peptidoglycan provides strength in the bacterial 
cell wall and enables the bacteria to resist osmotic lysis. 
It is possible to synthesise branched peptides by reactions on the side chain. Glutamic acid 
and aspartic acid have a further carboxyl group in the side chain which can react with the 
amino group of a second amino acid. Lysine and arginine have an amino and guanidine 
group respectively in the side chain which can react with the carboxyl group of a second 
amino acid.  
Branched peptides have been used in a variety of applications ranging from multiple 
antigenic peptide systems
[15]
 to gene carriers.
[16]
 Falciani et al.
[17]
 showed for drug-
conjugated branched peptides containing the human regulatory peptide neurotensin a 
retained or increased biological activity by multivalent binding. They also have a 
considerably higher in vivo activity compared to the corresponding peptide monomers due 
to the fact that they are very resistant towards proteolysis. 
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1.4 Solid Phase Peptide Synthesis (SPPS) 
 
The solid-phase peptide synthesis (SPPS) has been developed by R. B. Merrifield
[18]
 in 
1963. The previous practice of peptide synthesis in solution was very inefficient and the 
purification has been a major problem. The concept of SPPS involves the covalent binding 
of the growing amino acid chain on an insoluble resin. That way unreacted soluble 
reagents can easily be removed by washing and filtration of the resin. Merrifield used a 
polystyrene resin with CH2Cl groups on the surface (Merrifield resin). Today a range of 
resins and linkers are available e.g. Phenylacetamidomethyl (PAM) resin, Rink-Amide 
resin and Wang resin (Figure 13). 
 
Cl O
OH
Merrifield-resin Wang-linker
(used during Fmoc-SPPS)
PAM-linker
(used during Boc-SPPS)
O
NH
O
OH
Rink-Amide-linker
(used during Fmoc-SPPS)
NHFmoc
O
O
 
Figure 13: Active group on Merrifield resin surface and examples of linkers for some common resins in 
SPPS. 
 
The peptide synthesis on the resin proceeds from the carboxyl- to the amino terminus 
which is in reverse order of protein synthesis in vivo. First, the Nα-protected amino acid 
that is to form the C-terminal end of the peptide is bound through a cleavable linker to the 
resin. A frequently used Nα-protecting group is the Fmoc (9-fluorenylmethoxycarbonyl)-
protecting group which is base labile. This protecting group can be removed by secondary 
amines like piperidine. During the peptide synthesis it is also important to protect the 
functional groups of the side chains of the amino acids used. These protecting groups vary 
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in the different amino acids and need to be base stable and acid labile for Fmoc-SPPS 
(Figure 14). 
 
H3C
CH3
CH3
RH3C
CH3
CH3
O C R
O
R
Boc (tert-butyl-
carbonyl)
Lys, Trp
tBu (tert-butyl)
Tyr, Thr, Ser,
Glu, Asp
Trt (trityl)
His, Cys,
Asn, Gln
H3C
CH3
SO2
CH3
O
CH3
CH3
R R = Peptide
Pmc (pentamethyl-
chromansulfonyl)
Arg
 
Figure 14: Amino acid side chain protecting groups for Fmoc-Solid Phase Peptide Synthesis.[19] The 
protecting groups are acid labile and base stable. 
 
The Nα-protecting group is removed under the appropriate conditions (e.g. piperidine for 
Fmoc) and the resin is then washed and filtered to remove all soluble reagents. Now the 
carboxyl group of the amino acid is activated e.g. with BOP or PyBOP to enable the 
coupling step with the next Nα-protected amino acid. Under basic conditions BOP or 
PyBOP and the Nα-protected amino acid are added at the same time. The free carboxylic 
acid of the Nα-protected amino acid reacts with BOP or PyBOP and forms an active ester 
(Scheme 4 shows activation with BOP). The lone pair of the carboxyl oxygen attacks the 
positive charged phosphorus of the BOP reagent. A benzotriazololate is split of and 
attacks then the carboxyl group of the amino acid which creates an ester with a good 
leaving group. The amino group lone pair of the resin bound peptide attacks the activated 
carboxyl group and forms a peptide bond under loss of hydroxybenzotriazole (HOBt). The 
advantage of the PyBOP reagent is that no carcinogen hexamethylphosphoramide 
(HMPA) is produced during activation.  
The amino acid couplings for the peptide growth are characterised by high yields and 
reproducibility. Often an excess of soluble reagents is used to achieve a full conversion. 
To remove all soluble reagents after the coupling step the resin is washed and filtered. 
Now the cycle of Nα deprotection and amino acid coupling can be repeated as often as 
necessary.  
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(dimethylamino)-phosphonium
hexaf luorophosphate)
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(Benzotriazol-1-yl-oxytri-
pyrrolidinophosphonium
hexafluorophosphate)  
Scheme 4: Mechanism of activation in solid phase peptide synthesis and figures of BOB and PyBOP 
reagent. 
 
 
Deprotection
Activation
Coupling
Cleave peptide from resin and deprotection of side chain protecting groups
Repeat of steps
for each amino acid
N-alpha deprotection of resin bound peptide
Washing and filtration of resin to remove excess of soluble reagents
Activation of the designated amino acid´s carboxylic group and
coupling on resin bound peptide
Washing and filtration of resin to remove excess of soluble reagents
 
Scheme 5: Simplified scheme for solid phase peptide synthesis. 
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As soon as the desired peptide sequence is synthesised by SPPS, the crude peptide is 
separated from the resin. This is done under appropriate conditions which remove the 
protecting groups from the side chains and releases the peptide from the resin. For 
example a mixture of thioanisol (5.0%), ethanedithiol (2.5%), m-cresol (5.0%), water 
(5.0%) and TFA (82.5%) can be added to the peptide resin and left for some hours at room 
temperature. Finally, the crude peptide can be purified and analysed. 
The SPPS allows the synthesis of defined peptides which can even contain unnatural 
amino acids. The simplicity of the ever repeating steps in the SPPS also allows the 
automation of the entire process and offers the possibility to create compound libraries in 
combinatorial chemistry. A disadvantage of the SPPS is the possible aggregation of the 
growing peptide chains.
[19]
 The peptide chains are sometimes so intertwined that a further 
elongation of the peptide strand is no longer possible. The driving force of aggregation is 
the formation of hydrophobic interactions or hydrogen bonds. Therefore the synthesis of 
peptides by SPPS with more than 30 amino acids can be difficult. 
 
 
 
1.5 Protein/Peptide Binding to Nucleic Acids 
 
One particularly interesting and also challenging problem in molecular biology is to 
understand the ability of proteins to selectively bind to very specific targets on nucleic 
acids. 
The structural abundance of protein-nucleic acid interactions becomes more and more 
illustrated with the increasing number of well resolved X-ray structures of complexes 
described in literature. The very broad spectrum of folding variations of proteins and 
nucleic acids notably RNA do explain the structural abundance. Consequentially this leads 
to numerous types of recognition surfaces.
[20]
 To better appreciate interactions between 
nucleic acids and proteins or potential nucleic-acid-targeted molecules it is crucial to not 
only determine the structure of nucleic acid complexes but to also clarify their dynamic.
[21]
 
The X-ray resolution of complexes is however frequently impaired by crystallisation 
difficulties or measurement limitations. In such cases studies with simplified model 
systems may be investigated to afford valuable information. It is possible to determine a 
complex of the nucleic acid binding domain or a part of the domain and a short 
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polypeptide in absence of the extensive protein scaffold which recognises the nucleic acid 
binding domain.
[20]
 
The strength and specificity of peptide-nucleic acid complexes are defined through the 
orientation of chemical groups on the interface. Typically the attracting forces involved 
are a combination of hydrophobic, ionic and hydrogen bond interactions. Last but not least 
also water- or metal-mediated interactions are participating. 
Hitherto the general estimation of protein–nucleic acid complexes was based on the view 
that the task of the protein is to recognise and distinguish specific elements of nucleic 
acids by applying its tertiary structure. The protein envelopes the nucleic acid and offers 
certain binding pockets. Moderate changes in the conformation of the protein may take 
place to optimise the fit. This role allocation was found to be partially reversed in 
published peptide-RNA complexes.
[22]
 In these cases it was the RNA that wrapped itself 
around the attached peptide in the complex formation process. Here the tertiary structure 
of the RNA provided the binding framework and also pockets for specific binding.  
Prior to the RNA binding peptides are largely unstructured and develop only upon 
complex formation mostly α-helix[22, 23] or β-hairpin[24] structure. For example the HIV-1 
proteins Tat (trans-activator of transcription, 101 amino acids) and Rev (regulator of 
expression of virion proteins, 116 amino acids) are unstructured until binding to the 
mRNA motifs Tar (trans-activating response element) or Rre (Rev response element), 
respectively. The conclusion is that both RNA and peptide may contribute towards 
complex optimisation through conformational alterations. Some peptides require a helical 
structure in the first place to bind specifically to RNA
[25]
 and several α-helix peptides-
RNA complexes have been studied.
[26]
 Various peptide-DNA complexes
[27]
 have been 
investigated in the last decades, too. Conformational alterations of oligopeptides are also 
known to occur in peptide-DNA complexes. In such complexes the helicity of α-helix 
peptides increased during binding.
[28]
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1.6 α-Helix Stabilisation in Oligopeptides 
 
Helices are important recognition motifs and they are the largest class of secondary 
structure units in proteins. The average length of these units equals two to three helical 
turns.
[29]
 Separation of the α-helix motif from the tertiary protein structure usually results 
in peptides with random coil structure which lose much of their ability to specifically bind 
to the intended target. Different strategies have been developed for α-helix stabilisation in 
oligopeptides like the introduction of covalent side chain constrains, incorporation of 
unnatural amino acids and metal complexation.
[29]
 
One complete α-helix turn contains 3.6 amino acids where the side chains in position i, i + 
4, i + 7 and i + 11 locate on the same face of the α-helix.[30] Covalent bonds between the i 
and i + 4 or i + 7 side chain group reduce the conformational flexibility of the peptide and 
can lock segments of these peptides into helical formation. Common methods are lactam 
and disulfide bridges (Figure 15). The lactam bridge is formed of amide bonds between 
the side chains of Lys and Asp/Glu. The side chains are protected with Allyl for Glu and 
Asp and with Alloc for Lys during peptide synthesis. Treatment with tetrakis 
(triphenylphosphine) Pd(0) removes these groups without affecting the other protecting 
groups. The lactam formation can be performed between the carboxyl and the amino 
function ensuring completion of the reaction by activation with HATU.  
Disulfide bonds are formed via oxidation (in the air or with iodine) between cysteine side 
chains in position i and i + 4. The incorporation of D-Cys in position i and L-Cys in 
position i + 4 is required to realise a helical structure. The L,L-analogue peptides show a 
highly distorted helical structure and the L,D-analogue results in a random coil or β-sheet 
peptides.
[31]
 Lactam and disulfide bridges are a powerful tool to stabilise α-helix 
conformation but they are not always stable in cells.  
 
H-Lys-Glu-Ile-Leu-Arg-Lys-Leu-Leu-Gln-NH2
H-Thr-Trp-Ala-Arg-Asn-cys-Tyr-Asn-Val-Cys-Arg-Leu-Pro-NH2
S-S
C(O)-NH
Peptide with Lactam-Bridge
Peptide with Disulf ide-Bridge
 
Figure 15: Examples of peptides with α-helix stabilisation via lactam- or D-cys,L-Cys-disulfide-bridge. 
 
Chapter 1     Introduction 
19 
 
This limitation can be overcome by replacing one of the intramolecular hydrogen bonds of 
the main helix with a hydrocarbon bridge.
[30]
 Unnatural amino acids with olefin side 
chains are introduced in position i and i + 4 or i + 7. The hydrocarbon bridge is finalised 
via ring closure using Grubbs chemistry (Scheme 6). Introduction of unnatural amino 
acids have also been reported for α-helix stabilisation via disulfide bridges.[32, 33] Jackson 
et al.
[32]
 for example included the D and L form of N-Fmoc-S-(acetamidomethyl)-2-amino-
6-mercaptohexanoic acid (10, Scheme 6) into position i and i + 7 to achieve high helicity 
in an eight-residue peptide. 
 
FmocHN S N
H
CO2H O
A
B
10  
Scheme 6: A: Introduction of unnatural amino acids to stabilise α-helix structure via hydrocarbon bridge. B: 
Unnatural amino acid N-Fmoc-S-(acetamidomethyl)-2-amino-6-mercaptohexanoic acid (1) used 
for α-helix stabilisation via disulfide bridge. 
 
 
 
1.7 Transforming Growth Factor beta 1 (TGF-β1) 
 
The TGFB1 gene provides the instructions to produce the protein transforming growth 
factor beta 1 (TGFβ-1). This protein is a dimer of two identical peptides which are linked 
by disulfide bridges and consist of 112 amino acids. Each of these peptides is synthesised 
from a 390 amino acid long protein precursor by proteolytic processes.  
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The TGFβ-1 protein is found throughout the body and helps to control the growth and 
division of cells, the differentiation of cells, the cell movement and the apoptosis of 
cells.
[34]
 The protein also regulates inflammation and wound healing. After the stimulation 
of a receptor with TGFβ-1 the responds in the cell can be very different depending of the 
cell type and the state of cell differentiation.  
Interestingly the mRNA of TGF-β1 is not translated very well into the protein and protein 
binding on the GC rich stem loop between nt +77 to +106 of the mRNA (Figure 16) is 
believed to play an important role for the regulation of translation.
[35]
 The regulation 
seems to occur by protein complexes where currently only protein YB-1 is identified. YB-
1 (Y-box binding protein-1) is a RNA binding protein and functions as a transcription 
factor. It binds to the GC rich stem loop of the TGF-β1 mRNA and is important for the 
translation regulation.  
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Figure 16: The GC rich stem loop between nt +77 to +106 of the mRNA of TGF-β1 is believed to play an 
important role for the regulation of translation. 
 
The GC rich stem loop of the TGF-β1 mRNA is therefore an interesting target to learn 
more about the protein binding and therefore about the regulation of the translation. 
Binding test studies with a simplified peptide model system could afford valuable 
information.  
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1.8 Scientific Goals 
 
One goal in medical chemistry research is the synthesis of compounds (proteins and small 
molecules) which interact with nucleic acids to give control over processes like replication 
of DNA, translation of DNA into RNA and transcription of RNA into proteins. 
Compounds that interact with nucleic acid have to bind sequence-specifically in order to 
target solely a definite set of genes or organisms. 
This project tries to contribute to this scientific field by gaining new findings in two rather 
distinct aspects of research.  
Firstly the stereoselective synthesis of new constrained unnatural arginine mimetics should 
be planned and carried out. The planning should incorporate the following determining 
factors. The syntheses should be short, stereoselective and efficient and where possible 
also apply strategic concepts that are new to amino acid synthesis. 
Secondly the synthesised arginine mimetics should be used to prepare peptide libraries via 
the split and recombine method using macro-beads. These short peptides should then be 
used to investigate the binding to TGF-β1 mRNA as this could afford valuable information 
of the translation of the mRNA. 
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2. Results and Discussions 
 
2.1 Synthesis of Arginine Mimetics 
 
2.1.1 Introduction 
 
This project investigated hitherto untested synthetic options in the preparation of arginine 
mimetics. The following considerations influenced the decision on which target molecules 
were synthetically pursued. The syntheses should be rather short to provide efficient and 
economically attractive access to the target molecule. It was deemed highly desirable to 
ensure a high degree of stereoselectivity. The target compounds should be new or only 
known as racemates. Last but not least two key perceptions of many recent efforts which 
should also be consulted in this project were the introduction of rigidity and modifications 
of the guanidine moiety. 
2-Amino-5-iodopyrimidine (11, Figure 17) was identified to have interesting properties as 
a starting material that would meet some of the lined out requirements. It is commercially 
available and as an iodide opens opportunities to use efficient C-C coupling chemistry. It 
contains a ring system that would provide rigidity and includes the guanidine system. Also 
it opens the possibility to vary the basicity of any product through hydrogenation of the 
aromatic ring system. 
 
N N
I
NH2
11
2-Amino-5-iodopyrimidine 
Figure 17: Structure of commercially available 2-amino-5-iodopyrimidine. 
 
Based on this starting position the molecules 12 and 13 were targeted. They are related to 
arginine (14) but contain a constrained side chain (Figure 18). Similar structures are found 
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in natural products e.g. capreomycidine antibiotics where the non-proteinogenic amino 
acid capreomycidine 15 is a constituent. While 12 has not been reported previously 13 has 
been synthesised but only as a racemate.
[36]
 
 
H2N
OH
O
NH
H
N NH
H2N
OH
O
NHHN
NH
12 13
H2N N
H
OH
NH
NH2
O
N
H
NH
NH
H2N
O
OH
14 15
Arginine (2S, 3R)-Capreomycidine
(S)-2-Amino-3-(2-iminohexa-
hydropyrimidin-5-yl)-
propanoic acid
(S)-2-Amino-2-(2-iminohexa-
hydropyrimidin-5-yl)-
acetic acid
 
Figure 18: Structure of (S)-2-amino-2-(2-iminohexahydropyrimidin-5-yl) acetic acid (12), (S)-2-amino-3-
(2-iminohexahydropyrimidin-5-yl) propanoic acid (13), arginine and (2S, 3R)-capreomycidine. 
 
The synthetic efforts to prepare these compounds in both enantiomers and in their 
aromatic or reduced derivatives are described in the following chapter.  
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2.1.2 Synthesis of (S)/(R)-AAP and (S)/(R)-AIP) 
 
(S)/(R)-AAP (16, 17) and (S)/(R)-AIP (13, 18) (Figure 19) are four arginine derivatives 
which were considered to be of interest. These amino acids possess the same number of 
nitrogen and oxygen atoms and one additional carbon atom as arginine but differ from it 
by having a constrained side chain. The constrained analogues should show a reduced loss 
of entropy when binding to a nucleic acid target due to a diminished loss of torsional 
freedom. The stereocentres of (S)/(R)-AAP and (S)/(R)-AIP could be synthesised by the 
formation of one of the four bonds on the α-centre or a commercially available 
homochirals could be coupled to a pyrimidine ring. 
 
H2N N
H
CO2H
NH
NH2
arginine
HN N
NH2
NH2
CO2H
HN N
NH2
NH2
CO2H
18
(R)-AIP
13
(S)-AIP
N N
NH2
NH2
CO2H
N N
NH2
NH2
CO2H
17
(R)-AAP
16
(S)-AAP
 
Figure 19: Structure of (S)/(R)-2-amino-3-(2-aminopyrimidin-5-yl)-propanoic acid (16, 17), (S)/(R)-2-
amino-3-(2-iminohexahydropyrimidin-5-yl)propanoic acid (13, 18) and arginine. 
 
The advantage of coupling an amino acid derivative to the pyrimidine ring is that amino 
acid derivatives are commercially available with very high enantiomerical purity.  
 
 
2.1.2.1 Synthesis Planning 
 
The group of Richard F. W. Jackson has investigated a palladium catalysed cross-coupling 
reaction of substituted haloaromatics with organozinc reagents from iodoalanine derivative 
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19
[37, 38]
 (Scheme 7). Sufficient zinc activation is essential for the formation of the 
organozinc reagents. The organozinc reagents were prepared using commercial zinc dust 
which was then activated sequentially with 1,2-dibromoethane and TMSCl in dry DMF. 
The coupling reaction with haloaromatics were mediated by a palladium catalyst 
(Pd(PPh3)2Cl2 or Pd2dba3).
[38]
 
 
RHN CO2Me
I
RHN CO2Me
ZnI
RHN CO2Me
Ar
19 20 21
R = Fmoc or Boc
i ii
 
Scheme 7: Reagents and conditions: (i) activated Zn; (ii) Pd(PPh3)2Cl2 or Pd2dba3, electrophile, DMF, rt.
[38] 
 
Also a range of pyridyl amino acids (Figure 20) have been synthesised in the group of 
Richard F. W. Jackson by cross-coupling halopyridine with organozinc reagents based on 
an iodoalanine derivative 19.
[38]
 
 
 
Figure 20: Pyridyl amino acids.[38] 
 
The results of the Jackson group have shown that theirs is a simple and efficient concept to 
synthesise unnatural amino acids with high enantiomeric purity. Hence for this project a 
pathway for the synthesis of the arginine derivatives was chosen (shown in Scheme 8) 
based on the publications from the Jackson group.
[37, 38]
 The strategy begins with a 
palladium catalysed Negishi coupling of the commercially available 2-amino-5-
iodopyrimidine (11) and the enantiomerically pure (R) or (S) iodoalanine derivative (22). 
In the next step the Boc protecting group would be removed from the coupling product 
using TFA. A hydrogenolysis of the benzyl protecting group and a reduction of the 
heteroaromatic ring would be completed using hydrogen gas and a palladium catalyst.  
 
Chapter 2     Results and Discussions 
26 
 
HN N
NH2
NH2
CO2H
N N
NH2
NHBoc
CO2Bn
N N
NH2
I
BocHN CO2Bn
I
13 23 24 11 22
N N
NH2
NH2
CO2Bn
 
Scheme 8: Retrosynthetic analysis for the synthesis of amino acid 13 based on publications from Richard F. 
W. Jackson’s group.[37, 38] 
 
 
2.1.2.2 Negishi Coupling 
 
The Negishi coupling was published by Ei-ichi Negishi in 1977.
[39]
 Alkenyl or aryl halide 
are coupled to an organozinc compound using a nickel or palladium catalyst (Scheme 9). 
The best results for reaction rate, yield and stereoselectivity are obtained when organozinc 
compounds are coupled in the presence of Pd(0) catalysts.
[39]
 The active Pd(0) and Ni(0) 
complexes are relatively unstable but can be generated in situ from more stable Pd(II) and 
Ni(II) complexes. The Negishi coupling has the advantage that many functional groups are 
tolerated. The reason is that organozinc compounds are less reactive than other 
organometallic compounds with metals like lithium or magnesium.  
 
RX R´ ZnX R-R´
R = aryl, alkenyl, alkynyl
R´= aryl, alkenyl, allyl, benzyl
X = Cl, Br, I
L = ligand
NiLn or PdLn
 
Scheme 9: Principle of Negishi coupling. 
 
For the Negishi coupling of 11 and N-(tert-butoxycarbonyl)-3-iodo-L-alanine benzyl ester 
(Boc-beta-iodo-Ala-OBn, 22) the conditions from the Tabanella
[38]
 publication have been 
used. First zinc granular was activated in dry DMF with 1,2-dibromoethane and TMSCl. 
22 was added and after 6 hours the zinc insertion was complete (TLC). Pd(PPh3)2Cl2 and 
11 were added and the mixture was stirred for 15 hours at room temperature. Because the 
TLC monitoring showed still educt 11 the temperature was increased to 40 °C for 4 hours. 
The work up showed no coupling product and most of the organozinc reagent was 
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hydrolysed into pyrimidin-2-amine. In further attempts the reaction temperature was first 
increased to 55 °C and then to 120 °C but no coupling product was found in the work up. 
The catalyst was changed to Pd2(dba)3, different solvents like dry THF, dry NMI and dry 
NMP were tried and as ligands triphenylphosphine or tricyclohexylphosphine were added. 
The zinc activation was also changed. Zinc dust was used to increase the surface area and 
the zinc was activated in dry DMF with LiCl, 1,2-dibromoethane and TMSCl (Table 1).  
The palladium catalysed coupling between 11 and 22 was unsuccessful under these 
conditions. It was verified that the zinc insertion was performed by working up the 
mixture of activated zinc and 22 with D2O after 6 hours. The NMR shoved a full 
conversion into 5-deuteridepyrimidin-2-amine.  
 
 
Table 1: Attempts to cross-couple 11 and 22. 
Zinc 
activation* Catalyst Ligand 
Solvent 
(dry) 
Temp. 
[°C] 
Time 
[h] 
I Pd(PPh3)2Cl2 - DMF rt-40 18 
II Pd(PPh3)2Cl2 - THF 55 24 
II Pd(PPh3)2Cl2 - DMF 120 17 
II Pd2(dba)3 PPh3 NMI 120 5 
I Pd2(dba)3 PCyp3 NMP 100 18 
* Zinc activation I: zinc, dry DMF and 1,2-dibromoethane heated for 30 min. at 90˚C, TMSCl added at room 
temperature and stirred for 30 min., II: zinc dust plus dry LiCl on vacuum line for 20 min., dry DMF and 
1,2-dibromoethane added and heated for 30 min. at 90˚C, TMSCl added at room temperature and stirred for 
30 min. 
 
It was considered that the amino group of 11 might hinder the coupling. Normally anilines 
can be tolerated in coupling reactions with organozinc reagents as shown in the 
publication of Tabanella
[38]
 but the publication also mentions coupling problems in 
position 5 of the more acidic 2-amino-5-iodopyrimidine. So the amino group of 2-amino-
5-iodopyrimidine was protected with two benzyl protecting groups to investigate the 
coupling with this compound. 
The dibenzyl protection turned out to be difficult probably due to the delocalization of the 
amine lone pair of 11 into the aromatic ring system. Parameters like the nature of the base 
(NaOH, K2CO3, DBU), reaction time (0.5 h (MW) to 16 h), reaction temperature and 
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solvent system were investigated but just led to the monoprotected amine (Table 2). C. B. 
Reese
[40]
 and T. Saitoh
[41]
 published the dibenzyl protection of aromatic amines using 
sodium hydride as base. Using this strong base finally resulted in the dibenzyl protected 
amine 17 in good yields (Table 2, Scheme 10). 
 
Table 2: Investigated parameters for dibenzyl protection of 11. 
BnBr 
[eq.] 
Base (eq.) Solvent 
Time 
[h] 
Temp. 
[°C] 
Monoprotected 
[%] 
Diprotected 
[%] 
2.0 NaOH (2.2) water 
0.5 
(MW) 80 31 - 
2.9 K2CO3 (3.2) dry DMF 16 80 33 - 
2.9 K2CO3 (3.2) dry THF 16 80 34 - 
2.9 K2CO3 (3.2) dry MeCN 16 80 40 - 
5.9 K2CO3 (3.2) - 15 100 50 - 
2.9 DBU (2.9) dry DMF 16 80 39 - 
2.9 DBU (2.9) dry THF 16 80 39 - 
2.9 DBU (2.9) dry MeCN 16 80 39 - 
5.9 DBU (9.9) - 15 100 34 - 
2.5 NaH (3.2) dry THF 19 rt 14 78 
 
 
 
 
11 25
N N
NH2
I
N N
NBn2
I
i
 
Scheme 10: Reagents and conditions: (i) NaH, BnBr, THF, 0 °C – rt, 19 h at rt, 78%; Crystal structure of 25. 
 
The palladium catalysed coupling with zinc activation was then investigated between the 
dibenzylprotected pyrimidine 25 and the (S) iodoalanine derivative 22. Different catalyst 
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and ligand were investigated (Table 3) but it seems that position 5 of 25 is too unreactive 
for the Negishi coupling and no desired product was found in the work up. 
 
Table 3: Attempts to cross-couple 25 and 22. 
Zinc 
activation* 
Catalyst Ligand Solvent  
(dry) 
Temp. 
[°C] 
Time 
[h] 
II Pd(PPh3)2Cl2 - DMF 100 15 
II Pd(PPh3)2Cl2 - DMF 100 21 
II Pd(PPh2)2(Cp)2FeCl2 AsPh3 DMF 100 24 
* Zinc activation II: zinc dust plus dry LiCl on vacuum line for 20 min., DMF and 1,2-dibromoethane added 
and heated for 30 min. at 90˚C, TMSCl added at room temperature and stirred for 30 min. 
 
 
2.1.2.3. Heck Reaction 
 
A new synthesis strategy was devised, where the pyrimidine compound would be coupled 
to a 2-aminoacrylic acid derivative 26 via Heck coupling followed by stereoselective 
reduction of the double bond. The amino protecting group would be removed by an acid 
and the ester hydrolysed with a base (Scheme 11). 
 
HN N
NH2
NH2
CO2H
N N
NH2
NHR
CO2Me
N N
NH2
I
RHN CO2Me
13 27 28 11 26
R = Boc or Ac
N N
NH2
CO2Me
NHR
 
Scheme 11: New synthesis pathway for the synthesis of amino acid 13 based on Heck coupling and 
stereoselective reduction of the double bond. 
 
Heck reactions are palladium catalysed C-C couplings where a vinyl hydrogen is 
substituted with a moiety like aryl, vinyl or benzyl. A stoichiometric amount of base is 
required and the double bond is maintained in this process. 
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C. Chan et al. 
[42]
 reported a Heck coupling with Pd(OAc)2 and tri-o-tolylphosphine where 
the double bond of the terminal alkene moiety is created in situ from the commercially 
available compound 30 with four equivalents of triethylamine (Scheme 12). 
 
OMe
I
BocHN CO2Me
OTsBnO
PMBO
Pd(OAc)2
(o-tol)3P
TEA
Bu4NBr
OMe
BnO
PMBO
CO2Me
NHBoc
29 30 31  
Scheme 12: Synthesis of 31 by in situ formation of the double bond from compound 30 followed by Heck 
coupling to compound 29.[42] 
 
Hence the Heck coupling was investigated with compound 11 under these conditions but 
no coupling product was observed. The reaction temperature was then increased from 
80 °C to 120 °C and the solvent changed from acetonitrile to DMF but still no coupling 
product was discovered (Scheme 13). 
 
N N
NH2
I
BocHN CO2Me
OTs i or ii
12 30  
Scheme 13: Heck coupling reaction based on publication from C. Chan [42] did not work for compound 11 
with (i) Pd(OAc)2, Bu4NCl, Et3N, CH3CN, 80 °C, 72 h or (ii) Pd(OAc)2, PPh3, Et3N, DMF, 120 
°C, 88 h. 
 
The amino group of 11 was then protected with two Boc-protecting groups to exclude the 
free amino group as a possible inhibitor of the Heck coupling. Pyrimidine derivative 11 
was refluxed in THF with di-tert-butyldicarbonate (2.4 eq.) and 4-dimethyl-aminopyridine 
(0.26 eq.) to give the di-Boc-protected compound 32 with 97% yield (Scheme 14). 
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Scheme 14: Reagents and conditions: (i) Boc2O, DMAP, THF, reflux at 80 °C, 24 h, 97%. 
 
The Heck coupling with compound 30 and di-Boc-protected compound 32 was 
investigated and parameters like the type of the base, catalyst, reaction temperature and 
solvent system have been tested (Table 4) but no desired product was observed under the 
tested conditions. 
 
Table 4: Heck coupling attempts between 26 and 24. 
Base Catalyst Ligand Solvent Temp. [°C] Time [h] 
Et3N Pd(OAc)2 PPh3 CH3CN 80 24 
Et3N Pd(OAc)2 PPh3 DMF 110 18.5* 
NaHCO3+ 
TBACl Pd(PPh3)2Cl2 - NMP 130 18* 
CaCO3 + 
TBACl Pd(PPh3)2Cl2 - NMP 130 18* 
* Compound 26 was added after two hours of waiting time. 
 
M. J. Reno
[43]
 reported Heck coupling reactions also with 2-amino-5-iodopyrimidine as 
substrate which yielded 26% and 36% coupling product (Scheme 15). Therefore it was 
surprising not to find a coupling product at all even not with a small yield under the 
numerous applied conditions. 
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Scheme 15: Heck coupling using 2-amino-5-iodopyrimidine (11) published by M. J. Reno.[43] Reagents and 
conditions: (i) Pd(OAc)2, (o-tol)3P, Et3N, DMF, 100 °C, 5 h. 
 
It was thought that maybe the creation of the double bond in situ from 30 was the 
difficulty as the alkene was not found in the work-up. Therefore methyl-2-
acetamidoacrylate (35) was used instead of 30.  
Using Pd(OAc)2, triethylamine and tri-o-tolylphosphine in DMF at 100 °C resulted in no 
coupling product for 11 and 35 (Table 5, Entry 1) and 32 and 35 (Table 5, Entry 2). Traces 
of product have been found with the dibenzyl protected derivative 25 (Entry 3). Changing 
the base to NaHCO3 and adding Bu4NCl gave again just traces of product with derivative 
25 (Entry 4) but changing the catalyst to PdCl2 and working under dry conditions with dry 
DMF finally resulted in 80% of coupling product 37 (Entry 5). 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2     Results and Discussions 
33 
 
Table 5: Heck coupling attempts between pyrimidine derivatives and 35. 
 
Pyrimidine 
Deriv. 
Ene 
Deriv. Base Catalyst Ligand Solv. 
Temp. 
[°C] Prod. 
1 
N N
NH2
I 11  
AcHN CO2Me
35
 Et3N Pd(OAc)2 (o-tol)3P DMF 100 - 
2 
N N
NBoc2
I 32
 
AcHN CO2Me
35
 Et3N Pd(OAc)2 (o-tol)3P DMF 100 - 
3 
N N
NBn2
I 25 
AcHN CO2Me
35
 Et3N Pd(OAc)2 (o-tol)3P DMF 100 traces 
4 
N N
NBn2
I 25 
AcHN CO2Me
35
 
NaHCO3 
Bu4NCl Pd(OAc)2 (o-tol)3P DMF 100 traces 
5 
N N
NBn2
I 25 
AcHN CO2Me
35
 
NaHCO3 
Bu4NCl PdCl2 (o-tol)3P 
dry 
DMF 100 80% 
6 
N N
NBn2
I 25 
BocHN CO2Me
36
 
NaHCO3 
Bu4NCl PdCl2 (o-tol)3P 
dry 
DMF 70 70% 
 
 
For the coupling of 25 to methyl-2-(tert-butoxycarbonylamino)acrylate (36) the 
temperature had to be dropped to 70 °C otherwise the Boc protecting group was removed. 
Because of this lower temperature the reaction time had to be increased to 19 hours to give 
coupling product 38 in 70% yield (Entry 6 and Scheme 16). 
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Scheme 16: Reagents and conditions: (i) for R = Ac: PdCl2 (15 mol%), (o-tol)3P (15 mol%) , NaHCO3, 
Bu4NCl, dry DMF, 100 °C, 4 h, 80% (ii) for R = Boc: PdCl2 (20 mol%), (o-tol)3P (15 mol%), 
NaHCO3, Bu4NCl, dry DMF, 70 °C, 19 h, 70%. 
 
It was assumed that the cleavage of the benzyl protecting groups would require 
comparatively harsh conditions so the Heck coupling was also undertaken with the di-
Boc-protected pyrimidine 32 and compound 36 under dry conditions. This yielded in 30% 
coupling product 39 and 20% of the 5,5´-bipyridine 40 (Scheme 17). 
 
N N
NBoc2
I
BocHN CO2Me
MeO2C NHBoc
N
N
NBoc2
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N N
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N N
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Scheme 17: Reagents and conditions: (i) PdCl2 (20 mol%), (o-tol)3P (20 mol%) , NaHCO3, Bu4NCl, dry 
DMF, 70 °C, 19 h, 30%. 
 
One major issue is, that the reaction is very slow at 70˚C and after 19 hours reaction time 
both starting materials are still visible on the TLC. But at higher temperatures the Boc-
protecting groups get removed and the reaction ends in a complex mixture. Another issue 
is, that the di-Boc-protected pyrimidine 32 tends to couple with itself to afford a 5,5´-
bipyrimidine. This was also reported from J. R. Medina
[44]
 who published the synthesis of 
2-substituted-5-hydroxypyrimidines (Scheme 18). 5-Bromopyrimidines were subjected to 
a Miyaura-type aryl boronate synthesis. The di-Boc-protected 5-bromo-pyrimidine 41 
showed a significant amount of the symmetric biaryl in the reaction mixture, 
demonstrating the propensity to undergo Suzuki coupling under these mild conditions. The 
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biaryl formation was than minimized by using three equivalent of bis(pinacolato)diboron 
relative to the starting material.
[44]
  
 
N N
R
Br
41 R = NBoc2 42 R = NBoc2
N N
R
OH
ii
i
 
Scheme 18: Reagents and conditions: (i) Pd(OAc)2, KOAc, bis-(pinacolato)diboron (3 eq.), DMF, 85 °C, 
overnight; (ii) NaBO3 · 4 H2O, THF/H2O (1:1), rt, overnight, 96%. 
[44] 
 
During the Heck reaction the substitution is favoured on the sterically less hindered carbon 
of the olefin. The Heck product normally is preferentially generated as the 
thermodynamically more stable E-configured olefin. However exceptions are known in the 
literature. In cases of substrates with amino and carbonyl moieties (Z)-stereochemistry is 
strongly preferred.
[42, 43, 45, 46]
 So it was investigated if the (Z)- or the (E)-geometry was 
achieved in the Heck coupling of the pyrimidines. The NOESY of compound 31 and 32 
was measured and showed a cross peak between H-1 and H-2 (Figure 21) which defines 
the compounds as (Z)-coupling products. 
 
N
N NBn2
MeO2C N
H-2
RO
H-1
 
Figure 21: In a Heck-(Z)-coupling product H-1 and H-2 are close enough to show a cross peak in a NOESY 
measurement. 
 
Aside from the NOESY measurements it was tried to investigate the stereochemistry by a 
proton coupled 
13
C NMR experiment. Prasad
[45]
 determined the geometry of the double 
bond by proton coupled 
13
C NMR experiments. They measured the H-C three-bond 
coupling constant between the vinyl proton and the carbonyl carbon of the methyl ester 
(Figure 22) and compared the data to the known 
3
JCOOR, H coupling constants (cis = 8 Hz, 
trans = 12.6 Hz).
[47]
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OBn
OAc
H
CbzHN
OMeO  
Figure 22: Stereochemistry determined by Prasad[45] by measuring the H-C three-bond coupling constant 
between the vinyl proton and the carbonyl carbon in a proton coupled 13C NMR experiment. 
 
To verify the structure with the same method, a proton coupled 
13
C NMR was measured of 
compound 38. But also with over 4000 scans it was not possible to obtain a definite 
multiplet to determine the coupling constants (Figure 23 A). Ester 38 was than hydrolyzed 
with three eq. LiOH · H2O (Scheme 19) to eliminate the coupling of the carbonyl carbon 
with the protons of the methyl group. The proton coupled 
13
C NMR was than measured 
with compound 43 and resulted in an unresolved multiplet looking like a broad singlet for 
the carbonyl carbon of interest (Figure 23 B). 
 
 
 
   A)                                                B)                                          
 
 
 
 
 
 
 
 
 
Figure 23: Proton coupled 13C NMRs were measured with over 4000 scans to investigate the 
stereochemistry A) compound 38 showed an undefined multiplet for the carbonyl carbon of 
the methyl ester; B) compound 43 showed a broad singulet for the carbonyl carbon of the 
carboxylic acid. 
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Scheme 19: Reagents and conditions: (i) Hydrolysis of ester 38 with lithium hydroxide monohydrate (3 eq.), 
MeOH/THF/water (8:4:1), rt, 27 h, 95%. 
 
The proton coupled 
13
C NMR experiments have not provided the defined multiplet to 
determine the coupling constants. The problem might be that the carbonyl signal is not 
very strong in the 
13
C NMR anyway and H-C three-bond couplings are weak leading to a 
noisy poorly resolved signal from which the coupling constant cannot be determined. 
Fortunately, the stereochemistry was also resolved by crystal structure of the Heck 
coupling compound 37 (Figure 24).  
Crystals were grown using the Vapour Diffusion Method. Some material is dissolved in a 
solvent (S1) where it is good soluble in and placed in a closed vial with a small hole in the 
lid. This vial is placed in a larger closed vial containing a second solvent (S2) in which the 
material is less soluble in. Slow diffusion of S2 into the smaller vial and S1 out of that vial 
causes crystals to form. 
Various solvents were tested for S1 and S2 to crystallise 37 and 38 but resulted always in 
thin needles. Finally a crystallisation attempt with compound 37, chloroform (S1) and 
hexane (S2) gave large enough needles to determine the crystal structure. The structure 
shows a Z configuration with a disordered OCH3 group. The OCH3 group points in two 
orientations in the crystal. 
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Figure 24: Crystal structure of Heck coupling compound 37 with a disordered OCH3 group. The compound 
crystallises in thin needles where two orientations are present for the OCH3 group. 
 
In order to introduce chirality into the Heck coupling compounds the asymmetric 
hydrogenation was chosen. It uses inexpensive hydrogen gas and a very small amount of a 
chiral catalyst. This provides a powerful way to produce enantio-enriched compounds in 
large quantity without forming waste.  
 
 
2.1.2.4 Asymmetric Hydrogenation 
 
In the mid-sixties Geoffrey Wilkinson discovered the properties of chlorotris-
(triphenylphosphine)rhodium (RhCl(PPh3)3, Wilkinson catalyst) as soluble hydrogenation 
catalyst for unhindered olefins.
[48]
 By replacing the triphenylphosphine with a chiral 
phosphine an asymmetric hydrogenation takes place. Since the two enantiomers of a chiral 
drug molecule often have different effects on cells, it is important to be able to produce 
each of the two forms in high purity. Various chiral bidentate bisphosphine ligands have 
been developed for this purpose, some of the more popular being DIOP, BINAP, 
DUPHOS and DIPAMP (Figure 25). 
 
MeO2C NHAc
N
N
NBn2
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Figure 25: Examples of chiral bisphosphine ligands for the asymmetric hydrogenation. 
 
The well known and inexpensive bisphosphine ligand BINAP was chosen to test how the 
asymmetric hydrogenation would work out. Rh(COD)2BF4 (5 mol%) and (R)-BINAP 
(10 mol%) were added to compound 37 in a stainless steel high pressure reactor. The 
mixture was stirred in degassed methanol at room temperature with 5 bar hydrogen 
pressure. The reaction progress was checked by TLC but after 20 hours there was still no 
product produced. So the hydrogen pressure was increased to 7 bar which is the maximum 
pressure the hydrogen generator can produce. After a further 21 hours the reaction solution 
was worked up and 10% hydrogenation product was isolated by column chromatography 
(Table 6, Entry 1). The asymmetric hydrogenation was repeated with compound 38 at 
40˚C and with 7 bar of hydrogen from the reaction onset. The reaction was TLC 
monitored and showed a slower reactivity in comparison to compound 37. A very small 
product spot was visible on an especially long TLC (starting material and product have 
very similar Rf values) but the product could not be isolated by column chromatography 
(Table 6, Entry 2). 
 
 
Chapter 2     Results and Discussions 
40 
 
W. S. Knowles discussed the use of different phosphine ligands for olefins with a free 
carboxylic acid or an ester. Seven-membered bis(phosphines) like DIOP or BINAP are 
often inefficient when the free carboxylic acid is changed to a derivative such as an ester. 
In comparison five-membered bis(phosphines) like DIPAMP usually work quite well.
[48]
  
Therefore the hydrogenation was carried out with compound 38, 5 mol% Rh(COD)2BF4, 
10 mol% (S,S)-DIPAMP and 20 bar of hydrogen gas (using a hydrogen gas cylinder) in 
degassed methanol at room temperature. After 16 hours the TLC just showed a little 
product spot. So the hydrogen gas pressure was increased again to 35 bar and the reaction 
mixture was stirred for a further two days. Even with this high pressure the TLC showed 
still starting material after the two days. Because the starting material and the product have 
very similar Rf values the conversion was measured by a crude proton NMR (Figure 26). 
The NMR data demonstrate that 63% of the starting material was left and that 37% had 
been converted to the reduced product (Table 6, Entry 3). 
 
 
Figure 26: Crude proton NMR shows a conversion of 37% into the reduced product by hydrogenation with 
5 mol% Rh(COD)2BF4 and 10 mol% (S,S)-DIPAMP at 20 bar for 16 hours and two days at 
35 bar. 
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To improve the conversion an extensive literature research was undertaken which revealed 
that DUPHOS is frequently used as ligand especially for asymmetric hydrogenations with 
a Boc-protected α-enamides.[42, 49] Thus the reaction was carried out with compound 38, 
5 mol% Rh(COD)2BF4 and 10 mol% (S,S)-Me-DUPHOS at 35 bar of hydrogen pressure. 
After 20 hours a sample was taken and the crude proton NMR showed conversion of 80%. 
The mixture was left for further two days at 35 bar hydrogen pressure and the crude proton 
NMR showed now a conversion of 67% (Table 6, Entry 4). Because the yield had 
decreased already the reaction mixture was worked up. Purification with a very long 
column chromatography with CH2Cl2/MeOH (200:1) failed because of the too similar Rf 
values of product and starting material. A preparative TLC separation was then undertaken 
with CH2Cl2/MeOH (200:1) but the compounds absorbed very strongly to the silica which 
hindered most of the recovery. In the end just 7% product was recovered. A hydrogenation 
with compound 38, 5 mol% Rh(COD)2BF4 and 10 mol% (R,R)-Me-DUPHOS at 35 bar of 
hydrogen pressure showed a conversion of 70% after 48 hours (Table 6, Entry 5) and gave 
8% yield after the preparative TLC separation. The hydrogenation was then performed 
with compound 37, 5 mol% Rh(COD)2BF4 and 10 mol% (S,S)-Me-DUPHOS at 35 bar of 
hydrogen pressure for 24 hours. This yielded 92% product (Table 6, Entry 6) after column 
purification with hexane/ethyl acetate (1:2). Because the reaction works very well with 
compound 37 under these conditions the amount of used catalyst was reduced. Using 1 
mol% Rh(COD)2BF4 and 2 mol% (S,S)-Me-DUPHOS at 35 bar of hydrogen pressure gave 
a yield of 67% after column chromatography purification (Table 6, Entry 9). The amount 
of catalyst was increased again to 2 mol% which yielded 93% product using 4 mol% (S,S)-
Me-DUPHOS or 4 mol% (R,R)-Me-DUPHOS (Table 6, Entry 7 and 8). 
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Table 6: Asymmetric hydrogenation on compounds 37 and 38 with Rh(COD)2BF4 and different ligands. 
MeO2C NHBoc
N
N
NBn2
38
MeO2C NHAc
N
N
NBn2
37  
 Compound Rh cat. Ligand Time 
[h] 
H2 
[bar] 
Temp. 
[°C] 
Conv. 
[%] 
1 37 5 mol% (R)-BINAP 
(10 mol%) 
20 
21 
5 
7 
rt 10 
2 38 5 mol% (R)-BINAP 
(10 mol%) 
20 7 40 traces* 
3 38 5 mol% (S,S)-DIPAMP 
(10 mol%) 
16 
48 
20 
35 
rt 37** 
4 38 5 mol% (S,S)-Me-DUPHOS 
(10 mol%) 
48 35 rt 67** 
5 38 5 mol% (R,R)-Me-DUPHOS 
(10 mol%) 
24 35 rt 70** 
6 37 5 mol% (S,S)-Me-DUPHOS 
(10 mol%) 
24 35 rt 92 
7 37 2 mol% (S,S)-Me-DUPHOS 
(4 mol%) 
24 35 rt 93 
8 37 2 mol% (R,R)-Me-DUPHOS 
(4 mol%) 
24 35 rt 93 
9 37 1 mol% (S,S)-Me-DUPHOS 
(2 mol%) 
24 35 rt 67 
*determined by TLC; ** calculated by crude proton NMR 
 
All attempts to grow crystals from the hydrogenation product using the Vapour Diffusion 
Method resulted in needles which were too thin to determine a crystal structure. Hence the 
stereocentre was investigated with the Marfey’s reagent (FDAA).  
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2.1.2.5 Investigation of Stereocentre  
 
Marfey was the first to synthesise 1-fluoro-2,4-dinitropheyl-5-L-alanineamide (FDAA) 
and use it as a reagent for derivatisation of a D- and L-amino acid mixture.
[50]
 FDAA was 
prepared by substitution of one of the two fluorine atoms in 1,5-difluoro-2,4-
dinitrobenzene (DFDNB) by L-alanine amide (Scheme 20). FDAA then reacts with the 
amino group of L- and D-amino acids to yield diastereomers which can be separated by 
HPLC using a reverse phase column. The diastereomers may be detected at 340 nm with 
nanomolar sensitivity.
[50]
 
 
NO2
F
O2N
F
DFDNB
H2N
O
NH2
H
H3C
NO2
O2N
F
H
N
O
NH2
H
H3C
L-Alanine Amide FDAA  
 
Scheme 20: Synthesis of 1-fluoro-2,4-dinitropheyl-5-L-alanineamide (FDAA) by Marfey[50] using L-Ala-
NH2·HCl, 1 M NaOH, acetone, anhydrous MgSO4 and 1,5-difluoro-2,4-dinitrobenzene 
(DFDNB). 
 
To synthesise the diastereomers it is necessary to have a free amine group on the amino 
acid. So the hydrogenation products 44 and 45 prepared with ligand (S,S)-Me-DUPHOS 
and ligand (R,R)-Me-DUPHOS were refluxed with 6 M HCl. This removed the acetyl 
protecting group and hydrolysed the ester to give HCl salts 46 and 47 in 98% yield 
(Scheme 21). 
 
AcHN CO2Me
N
N
NBn2
H2N CO2H
N
N
NBn2
HCl
44 (S) 46 (S)
45 (R) 47 (R)
i
 
Scheme 21: To synthesise diastereomers using the Marfey´s reagent it was necessary to remove the acetyl 
protecting group. Reagents and conditions: (i) 6 M HCl, 110 °C, 6 h, 98%. 
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The diastereomers were prepared by stirring a mixture of FDAA (1.1 eq.), Cs2CO3 (20 eq.) 
and 46 respectively 47 in acetone/water (1:1) at 40 °C for two hours (Scheme 22). The 
solvent was removed under reduced pressure and the resulting orange solids were used 
crude for the HPLC experiments (Figures 27 and 28). 
 
NO2
H
N
F
O2N
NH2
O
CH3
H
FDAA
L
NO2
H
N
NH
O2N
NH2
O
CH3
H
NO2
H
N
HN
O2N
NH2
O
CH3
H
N
N
N
O
OH
N
N
N
HO
O
L L
DL
HPLC
(C18 reverse-phase)
acetone/water,
Cs2CO3, 40°C, 2 h
L,L-diastereomers are eluted from column before D,L-diasteromers
Stronger intramolecular H-bonding in D,L- than in L,L-diastereomers
48 49
HO2C NH2
N
N
NBn2
HCl
46 (S)
47 (R)
 
 
Scheme 22: Synthesis of diastereomers 41 and 42 using Marfey´s reagent FDAA. The diastereomers elute 
differently from the HPLC (C18 reverse-phase). The L,L-diastereomer elutes first because of 
stronger intramolecular H-bonding in the D,L- than in the L,L-diastereomer. 
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The D,L- and the L,L-diastereomer were analysed by HPLC (Dionex Ultimate 3000, C18 
reverse phase column, 5 μm particle size, 15 cm × 6.0 mm). A linear gradient of 100% 
TEAP buffer (50 mM, pH 3.0) to 100% MeCN over 50 min. was used (Figure 27 and 28). 
 
 
Figure 27: HPLC (C18 reverse-phase column) run of diastereomers 48 (red) and 49 (blue) using a linear 
gradient of 100% TEAP buffer (50 mM, pH 3.0) to 100% MeCN over 50 min. 
 
 
Figure 28: Expanded region of Figure 9 showing elution peaks for compound 48 (red) and 49 (blue).       
Red: high peak at 26.13 min. and small peak at 27.30 min., calculated ee = 98; Blue: high peak 
at 27.20 min. and small peak at 26.02 min., calculated ee = 96. 
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The red HPLC run shows that compound 48 synthesised with the (S,S)-Me-DUPHOS 
ligand gave a major peak at 26.1 min. and a minor peak at 27.3 min. The enantiomeric 
excess calculated from the peak areas is 98. The blue HPLC run shows that compound 49 
synthesised with the (R,R)-Me-DUPHOS ligand gave a high peak at 27.20 min. and a 
small peak at 26.02 min. The enantiomeric excess calculated from the peaks areas is 96. 
The L,D-diastereomer has stronger intramolecular hydrogen bonding and elutes therefore 
after the L,L-diastereomer from a reverse phase column. That confirms that the (S,S)-Me-
DUPHOS ligand gave the product 44 with a S-stereocentre and (R,R)-Me-DUPHOS ligand 
gave the product 45 with a R-stereocentre. 
The enantiomeric excess of the asymmetric hydrogenation with catalyst Rh(COD)2
+
 and 
ligand Me-DUPHOS was measured by HPLC (Shimadzu LC10A VP, ODH-column, 
hexane/isopropanol (20:80), 25°C). Compound 44 was produced with a S-stereocentre in 
an enantiomeric excess of 98 and compound 45 was produced with a R-stereocentre in an 
enantiomeric excess of 99 (Table 7). 
 
Table 7: Asymmetric hydrogenation with catalyst Rh(COD)2 and ligand Me-DUPHOS provided products in 
high yields and high enantiomeric excess. 
44 (S)-enantiomer 45 (R)-enantiomer
AcHN CO2Me
N
N NBn2
AcHN CO2Me
N
N NBn2
 
Rh(COD)2 Me-DUPHOS Product Yield ee 
5 mol% (S,S) 10 mol% 37 92% 98 
2 mol% (S,S) 4 mol% 37 93% 98 
2 mol% (R,R) 4 mol% 38 93% 99 
 
 
2.1.2.6 Cleavage Attempts of Benzyl Protection 
 
In the literature several examples are known for N-debenzylation from an aromatic amine 
by hydrogenolysis using palladium on carbon
[51]
 as catalyst. Also palladium hydroxide is 
widely used for reductive N-debenzylation
[52]
 and was chosen to reduce the pyrimidine 
ring and to remove the benzyl protecting groups in one step.  
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46 was treated with palladium hydroxide in methanol under hydrogen gas at room 
temperature but no reaction occurred and all starting material was recovered (Scheme 23). 
The hydrogen pressure was increased and at 15 bar the pyrimidine ring was reduced but 
both benzyl protecting groups remained. No debenzylation occurred even after increasing 
the hydrogen pressure to 30 bar (Scheme 23). 
 
H2N CO2H
N
N
NBn2
HCl
H2N CO2H
NH
N
NBn2
HCl
i
ii
46 (S)
47 (R)
50 (S)
51 (R)  
Scheme 23: Reagents and conditions: (i) 46 (S), Pd(OH)2, H2, 1 bar, degassed MeOH, rt, 24 h or 39 (S), 
Pd(OH)2, H2, 7 bar, degassed MeOH, rt, 24 h; (ii) 46 (S), Pd(OH)2, H2, 15 bar, degassed MeOH, 
rt, 24 h, 99% or 47 (R), Pd(OH)2, H2, 30 bar, degassed MeOH, rt, 24 h, 99% 
 
Another method for N-debenzylation involves transfer hydrogenation catalysed by 
palladium on carbon with ammonium formate.
[53]
 This method was also successful in case 
of debenzylation for aromatic amines.
[54]
 
A mixture of compound 46, ammonium formate (13 eq.) and palladium on carbon (10 
w%) was refluxed in methanol (Scheme 24). The reaction was monitored by TLC but 
showed no reaction even after 24 hours and the starting material was recovered in the 
work up.  
 
H2N CO2H
N
N
NBn2
HCl
i
46 (S)  
Scheme 24: Reagents and conditions: (i) 46, Pd/C (10 w%), NH4HCO2 (13 eq.), MeOH, 70 °C (reflux), up 
to 24 h. 
 
Chapter 2     Results and Discussions 
48 
 
Literature also illustrates the N-debenzylation with sodium in liquid ammonia.
[55]
 The 
sodium metal is added to ammonia at −78 °C and dissolves. Each dissolving sodium atom 
provides an electron into the liquid ammonia which solvates the sodium cation and the 
electron. The appearing blue colour is characteristic of a solution containing solvated 
electrons. This method was also applied in case of debenzylation for aromatic amines.
[56, 
57]
 The yields of the debenzylation for aromatic amines have been low (20% for Schwarz 
et al.
[57]
 and 40% crude for Young et al.
[56]
) but it was worth considering the method.  
 
BocHN CO2H
N
N
NBn2
52
i
 
Scheme 25: Schematic construction of attempted reduction with reagents and conditions: (i) compound 52, 
Na, liquid ammonia, dry THF, −78 °C to −30 °C, 1.5 hours at −30 °C. 
 
Reductive N-debenzylation with sodium and liquid ammonia was attempted with 2-amino 
pyrimidine compound 52 (Scheme 25). Sodium was added to liquid ammonia at −78 °C. 
The cooling bath underneath the flask was then removed and the mixture stirred for 1.5 
hours at −30 °C. According to TLC a reaction occurred. The substrate was transformed to 
several products of which none could be isolated or identified. The crude NMR did not 
indicate the presence of the desired product. 
In an extensive literature research a publication of C. B. Reese
[58]
 was found. Ammonium 
cerium(IV)nitrate (CAN) was used for oxidative di-N-debenzylation of 5-bromo-2-
(dibenzylamino)pyridine (53). Further publications
[59]
 reported that CAN is effective for 
N-debenzylation of tertiary amines but not of secondary amines. Reese states in the article 
that they were pleasantly surprised to find that the treatment of 53 with an excess of CAN 
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was effective
[60]
 (Scheme 26). Both benzyl protecting groups have been removed and the 
reaction was quenched with saturated aqueous sodium hydrogen carbonate. After filtration 
the product was transferred into the organic layer by washing with ethyl acetate.  
 
N
Br
NBn2 N
Br
NH2
i
53 54  
Scheme 26: Reagents and conditions: (i) CAN (5 eq.), MeCN/H2O (9:1), rt, 30 min.
[58] 
 
The oxidative di-N-debenzylation of 46 was attempted under the same conditions as 
described but the reaction was left for three hours instead of 30 minutes (Scheme 27). The 
work up was problematic because some starting material, the side product of N-
debenzylation and main product of di-N-debenzylation stayed together with the CAN in 
the water layer. The product was precipitated by changing the pH number of the water 
layer from 1 to 6 with 3 M NaOH which yielded in a yellow solid. The NMR showed the 
product but with impurities (Figure 29). 
 
H2N CO2H
N
N
NH2
H2N CO2H
N
N
NBn2
i
46 55
HCl 2 HNO3
 
Scheme 27: Reagents and conditions: (i) 46, CAN (5 eq.), MeCN/H2O (9:1), rt, 3 h. 
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Figure 29: 1H NMR in D2O of compound 48 with impurities. 
 
To increase the solubility of the product in organic solvents the reaction was repeated with 
compound 44 which contains an acetyl and an ester protecting group. Because the reaction 
was not completed with compound 46 the reaction time was increased to 6 hours and the 
amount of CAN was increased to 6 eq. (Scheme 28). 
 
AcHN CO2Me
N
N
NBn2
AcHN CO2H
N
N
NH2
i
44 56
HNO3
 
Scheme 28: Reagents and conditions: (i) 44, CAN (6 eq.), MeCN/H2O (9:1), rt, 6 h, 92%. 
 
During the work up it became apparent that the product was again in the water layer. This 
time the CAN was precipitated as brown solid by changing the pH number of the water 
layer from 1 to 12 with 3 M NaOH. The solvent from the water layer was removed under 
reduced pressure and the resulting light yellow solid was dried. Methanol was added to the 
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solid and the sodium hydroxide was filtered off from the resulting yellow solution. After 
removing the solvent again the NMR confirmed the synthesis of compound 56 (Figure 
30).  
 
 
Figure 30: 1H NMR in D2O of compound 56. 
 
The IR showed broad NO3

 peaks at 1567 cm
–1
 (N-O asymmetric) and at 1385 cm
–1
 (N-O 
symmetric). It was not possible to get a mass spectrum of the product. It could be that not 
all cerium was precipitated by changing the pH number from 1 to 12 and the cerium 
caused problems by the measurement of the mass spectrum. It could also be that the 
cerium ion coordinates to the guanidine part of the product. Several compounds have been 
published where metal ions coordinate to the guanidine part of pyrimidin-2-amine 
derivatives (Figure 31). 
 
Chapter 2     Results and Discussions 
52 
 
N N
NH2
I
Ag N N
NH2
Ph
Ag N N
NH2
Ph
N N
NH2
CuCuCN C N
N N
NH2
Ni2+
Cl
Cl
N N
NH2
Ni2+
Cl
Cl
N N
NH2
N N
NH
NN
HN
Sn4+
Br
Br Br
Br
N
N
Sn4+
Br
Br Br
Br
N
N
NH2
NH2
 
Figure 31: Examples of pyrimidin-2-amine derivatives with coordinated metal ions on the guanidine part. 
 
An acetyl deprotection was attempted with compound 56. The solid was refluxed in 3 M 
hydrogen chloride solution for six hours. The crude NMR did indicate that the compound 
decomposed and the aromatic ring hydrolysed. So the reaction time was decreased by up 
to 3 hours but the compound still hydrolysed.  
Because the synthesis came to a standstill there it was tried to improve the promising 
looking di-N-debenzylation of compound 46 (Scheme 20). The resulting product lacks the 
acetyl protecting group but the work up was difficult and the resulting yield small. 
Because all the reaction products stay in the water layer and cannot be separated it was 
attempted to reach full conversion. Parameters like the amount of CAN, solvent ratio, 
reaction time and reaction temperature were investigated (Table 8). 
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Table 8: Investigation of different parameters for di-N-debenzylation. 
CAN
MeCN/H2O
H2N CO2H
N
N
NH2
2 HNO3
H2N CO2H
N
N
NBn2
HCl
5546  
Entry CAN [eq.] MeCN/H2O Temp. Time [h] 
1 6.0 6:1 rt 7 ½ 
2 8.0 8:1 30 °C 24 
3 8.2 4:1 rt 24 
4 6.0 2:1 rt 5 
5 6.0 4:1 rt 7 ½ 
 
First the amount of CAN was increased to six equivalents, the reaction time was increased 
to 7 ½ hours and the solvent ratio was changed to MeCN/H2O 6:1 (Table 8, Entry 1). The 
proton NMR looked promising but it also showed a still uncompleted debenzylation. 
Therefore the amount of CAN was increased to eight equivalents, the reaction time was 
increased to 24 hours and the temperature was increased to 30 °C (Table 8, Entry 2). The 
proton NMR still showed a reaction mixture. Because the NMR of the reaction with the 
solvent ratio of MeCN/H2O 6:1 looked more promising, the solvent ratio was changed to 
MeCN/H2O 4:1 (Table 8, Entry 3). The proton NMR showed an increased conversion but 
the debenzylation was not complete. Therefore the solvent ratio was changed to 
MeCN/H2O 2:1 (Table 8, Entry 4) which resulted in a mixture of mono and di deprotected 
products. The conversion of the reaction was decreased compared to entry 3. The solvent 
ratio was changed back to MeCN/H2O 4:1 and the reaction time was decreased to 7 ½ 
hours to minimise possible decomposing (Table 8, Entry 5). The proton NMR showed a 
product mixture with uncompleted debenzylation. That is very problematic because the 
different products stay in the water layer and cannot be separated by column 
chromatography or recrystallisation. 
The oxidative di-N-debenzylation appeared to be more promising than the reductive di-N-
debenzylation. But it also seemed that the cerium metal ion coordinated to the guanidine 
part of the deprotected product causing difficulties in the work up and characterisation. 
Therefore a different oxidation method without metal ions was undertaken. In the 
literature the debenzylation of di-protected amines with N-iodosuccinimide (NIS)
[61]
 gave 
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high yields for the removal of one benzyl group with three equivalents NIS and yields of 
50 to 72% for the di-N-debenzylation with ten equivalent NIS. 
Compound 44 and ten equivalents NIS were stirred in dry dichloromethane at 25 °C under 
dry conditions while the flask was protected from ambient light. According to TLC no 
reaction occurred even after leaving the reaction for 23 hours. This was a significant 
problem because without the removal of the benzyl protecting groups the guanidine moity 
of the amino acid cannot bind.  
 
 
2.1.2.7 Altered Strategy with PMB Protection 
 
A synthesis pathway with 4-methoxybenzyl as protecting group instead of the benzyl 
protecting group was pursued while working on the di-N-debenzylation. The advantage of 
the 4-methoxybenzyl protecting group (PMB) is that it can be removed with trifluoroacetic 
acid.
[62]
 
The synthesis starts with di-protection of 11 with 4-methoxybenzyl chloride. The 
protected pyrimidine compound would be coupled to a 2-aminoacrylic acid derivative via 
Heck coupling followed by stereoselective reduction of the double bond. All protecting 
groups would be removed under acidic conditions and the aromatic ring of compound 16 
reduced with hydrogen (Scheme 29). 
 
N N
NH2
I
N N
N(PMB)2
CO2Me
NHAc
N N
NH2
CO2H
NH2
N N
N(PMB)2
NHAc
CO2Me
HN NH
NH
CO2H
NH2
13 16 57 58 11
 
Scheme 29: Retrosynthetic analysis for the synthesis of amino acid 13. 
 
The benzyl protecting group and the 4-methoxybenzyl protecting group have a similar 
structure. Therefore the reaction conditions which have been successful for the di-
benzylation have been applied for the reaction. Compound 11 was reacted with three 
equivalent sodium hydride and five equivalent 4-methoxybenzyl chloride (59). at room 
temperature under dry conditions. The reaction was monitored by TLC but after 21 hours 
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reaction time at room temperature most of the starting material was still unreacted. The 
temperature was increased to 30 °C and the mixture was stirred for further 23 hours until 
most of the starting material was converted. Because the reaction at room temperature was 
too slow it was decided to perform the reaction at 30 °C which gave a yield of 91% 
(Scheme 30). 
 
N N
NH2
I
N N
N
IO
Cl
O O
11 59 60
i
 
Scheme 30: Reagents and conditions: (i) 11, sodium hydride (3 eq.), 4-methoxybenzyl chloride (5 eq.), dry 
THF, 0 °C to 30 °C, 23 hours at 30 °C, 91%. 
 
The most successful condition for the Heck coupling of di-benzyl protected 25 (Table 5, 
Entry 5) has been used to attempt the Heck coupling of 60. This condition, using alkene 
35, PdCl2, NaHCO3, Bu4NCl and tri-o-tolylphosphine in dry DMF at 100 °C resulted in no 
coupling product (Table 9, Entry 1). To investigate if the product decomposed under this 
condition the reaction temperature was decreased to 60 °C but no reaction occurred and 
both staring materials have been recovered. The same outcome was reached at 90 °C. 
Therefore the amounts of catalyst and ligand were increased to 20 mol% and 40 mol%, 
respectively. This resulted in a 43% yield of coupling product 61 at 110 °C (Table 9, Entry 
4). The highest yield (62%) for the Heck coupling between 60 and 35 was achieved with 
30 mol% catalyst and 30 mol% ligand at 100 °C (Table 9, Entry 5). 
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Table 9: Investigation of different parameters for Heck coupling between compound 35 and 60. 
N N
N(PMB)2
I
AcHN CO2Me
N N
N(PMB)2
NHAc
CO2Me60 35 61
dry DMF
 
Entry 
PdCl2 
[mol%] 
(o-tol)3P 
[mol%] 
NaHCO3 
[eq.] 
Bu4NCl 
[eq.] 
Temp. 
[°C] 
Time 
[h] 
Yield 
[%] 
1 15 15 2.0 1.2 100 23 - 
2 15 15 2.0 1.2 60 2.5 - 
3 15 15 2.0 1.2 90 3 - 
4 20 40 2.0 1.2 110 24 43 
5 30 30 2.0 1.2 100 22 62 
 
The NOESY of compound 61 showed a cross peak between H-1 and H-2 (Figure 32) 
which defines the compound as (Z)-coupling product.  
 
N
N N(PMB)2
MeO2C N
H-2
RO
H-1
 
Figure 32: In a Heck-(Z)-coupling product H-1 and H-2 are close enough to couple and show a cross peak 
in a NOESY measurement. 
 
For introducing chirality into the Heck coupling compound 61 the asymmetric 
hydrogenation was chosen which has been very successful with the di-benzyl protected 
compound 37. The most successful condition for the asymmetric hydration of di-benzyl 
protected 25 (Table 6, Entry 7 and 8) has been used to attempt the asymmetric hydration 
of 61. The reaction was carried out with compound 61, 2 mol% Rh(COD)2BF4, 4 mol% 
(S,S)-Me-DUPHOS and 35 bar of hydrogen gas (using a hydrogen gas cylinder) in 
degassed methanol at room temperature and yielded in 7% product. To increase the yield 
the amount of catalyst and ligand has been doubled and the hydrogen gas pressure was 
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increased to 38 bar. This lead to a yield of 90% for the reaction with (S,S)-Me-DUPHOS 
and 91% for the reaction with (R,R)-Me-DUPHOS (Table 10). 
 
Table 10: Asymmetric hydrogenation with catalyst Rh(COD)2 and ligand Me-DUPHOS provided products 
in high yields and high enantiomeric excess. 
62 (S)-enantiomer 63 (R)-enantiomer
AcHN CO2Me
N
N N(PMB)2
AcHN CO2Me
N
N N(PMB)2
 
Rh(COD)2 Me-DUPHOS Product Yield ee 
4 mol% (S,S) 8 mol% 57 90% 99 
4 mol% (R,R) 8 mol% 58 91% 99 
 
The enantiomeric excess of the asymmetric hydrogenation compounds 62 and 63 was 
measured by HPLC (Shimadzu LC10A VP, ODH-column, hexane/isopropanol (20:80), 
25°C). 
Crystallisation of compound 62 and 63 in different solvent systems just resulted in long 
thin needles. The X-ray data are not good enough to determine the absolute configuration 
of the stereocentre. There have been similar problems with the crystallisation of the 
dibenzyl protected asymmetric compounds 44 and 45. The configuration of them was then 
determined by preparing diastereomers with FDAA (Scheme 15). The L,D-diastereomer 
has stronger intramolecular hydrogen bonding and elutes therefore after the L,L-
diastereomer from a C 18 reverse phase column. The results showed (Figure 9 and 10) that 
the asymmetric hydrogenation of compound 37 with the (S,S)-Me-DUPHOS ligand 
resulted in the product with a S-stereocentre and the reaction with the (R,R)-Me-DUPHOS 
ligand resulted in the product with a R-stereocentre. Because of the similarity between 
compounds 37 and 61 (Figure 33) it was assumed that the achieved results also apply for 
compound 61. 
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Figure 33: Figure shows the similarity between the structures of compounds 37 and 61. 
 
It is known that the 4-methoxybenzyl protecting group can be removed by trifluoroacetic 
acid.
[62]
 But there are also publications where the 4-methoxybenzyl protecting group was 
removed by hydrochloric acid
[63]
 or hydrobromic acid
[64]
, respectively (Scheme 31). 
 
N N
N N
N
H PMB N(PMB)2
R
i ii
N N
NH2
R
N N
NH2
64 65
66 67
A) B)
Scheme 31: Reagents and conditions: A) (i) 64, 3 M hydrochloric acid, 110 °C, 30 h, 59%;[63] B) (ii) 66, 
5.7 M hydrobromic acid in toluene, reflux, 8 h, 66%.[64] 
 
It was attempted to remove the PMB and acetyl protecting groups as well as cleave the 
ester in one step. Compound 62 was refluxed in 3 M hydrochloric acid for 3.5 hours. After 
the work up the proton NMR showed that the reaction resulted in a mixture of deprotected 
64 and still di-PMB protected 63 (Scheme 32, i).Therefore the reaction time was increased 
to six hours what yielded in a product mixture of deprotected 64 and mono-PMB protected 
65 (Scheme 32, ii). 
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Scheme 32: Reagents and conditions: (i) 62, 3 M HCl, 110 °C, 3 ½ h; (ii) 57, 3 M HCl, 110 °C, 6 h. 
 
The desired fully deprotected product and the partly deprotected products are very polar 
and cannot be separated easily by column chromatography. As a result it is important to 
achieve a conversion of 100% for the reaction. This was realised by a two step reaction 
(Scheme 33). First compound 62/63 was heated for four hours in TFA to remove the 4-
methoxybenzyl protecting groups. The TFA was removed under reduced pressure and the 
crude product was refluxed in 3 M hydrochloric acid for four hours. That gave the fully 
deprotected arginine derivatives 16 and 17, respectively in quantitative yield. By reducing 
the aromatic ring of 16 and 17 via hydrogenation on Pd(OH)2 two further arginine 
derivatives have been synthesised (Scheme 33). 
 
HN NH
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Scheme 33: Reagents and conditions: (i) TFA, 50 °C, 4 h; (ii) 3 M HCl, 110 °C, 4 h, quant. ; (iii) Pd(OH)2, 
H2, H2O, 15 bar, rt, 24 hours, quant. 
 
 
2.1.2.8 Summary 
 
These interesting arginine mimetics were all synthesised with very high stereoselectivity 
in both enantiomers (Figure 34). They could show intriguing binding properties towards 
nucleic acid when build into peptides. In contrast to arginine the guanidine side chain is 
conformationally constrained. This should result in a favourable entropic component when 
the peptide binds toward a nucleic acid target. The constrained analogues should show a 
reduced loss of entropy when binding due to a diminished loss of torsional freedom. This 
could also improve the selectivity for a target relative to peptides containing arginine with 
its highly flexible side chain instead.  
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NH2
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Figure 34: Structure of the stereoselective synthesised arginine mimetics. 
 
All four arginine mimetics build into the peptide can bind towards the base and the 
backbone of the nucleic acid target. The aromatic and partly planar character of the 
arginine derivatives 16 and 17 may open additional binding opportunities by intercalation 
between base pairs of DNA.  
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2.1.3 Synthetic Efforts towards (S)/(R)-AAA and (S)/(R)-AIA 
 
(S)/(R)-AAA (70, 71) and (S)/(R)-AIA (12, 72) (Figure 35) are two possible arginine 
mimetics which were considered to be of interest. These amino acids possess the same 
number of carbons, nitrogens and oxygens as arginine but have a constrained side chain. 
As mentioned before the constrained analogues should show a reduced entropy loss by 
binding to a nucleic acid. To realise the synthesis of the arginine mimetics it was 
necessary to connect the stereocentre directly to the amino tetrahydropyrimidine ring. 
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H
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N N
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CO2HH2N
N N
NH2
CO2HH2N
HN NH
NH
CO2HH2N
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(R)-AAA
70
(S)-AAA
72
(R)-AIA
12
(S)-AIA
 
Figure 35: Structure of (S)-2-amino-2-(2-aminopyrimidin-5-yl)acetic acid (70), (R)-2-amino-2-(2- 
aminopyrimidin-5-yl)acetic acid (71) (S)-2-amino-2-(2-iminohexahydropyrimidin-5-yl)acetic 
acid (12), (R)-2-amino-2-(2-iminohexahydropyrimidin-5-yl)acetic acid (72) and arginine. 
 
 
2.1.3.1 Synthesis Planning 
 
The chosen pathway is based on a publication of P. Cali and M. Begtrup.
[65]
 They 
synthesised 1-hydroxypyrazole α-amino acids by introducing the glycine functionality 
with diethyl N-Boc iminolate (73) via Grignard reaction. The racemic amino acid was 
realised by reaction with lithium hydroxide at room temperature and hydrochloric acid in 
Et2O at 60 °C (Scheme 34). 
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Scheme 34: Reagents and conditions: (i) i-PrMgCl, THF, 0 °C, 30 min., then cooling to −78 °C, 3 h; (ii) H2 
(1 atm), 10% Pd/C, MeOH, 0 °C, 30 min.; (iii) LiOH, rt, 4 h; (iv) 2 M HCl in Et2O, 60 °C, 
30 min.[65] 
 
The synthesis plan for the amino acids starts with the commercially available 2-amino-5-
iodopyrimidine. The iminolate 74 and the di-benzyl protected pyrimidine 25 would be 
coupled by a Grignard reaction. After formation of the stereocentre as racemate the Boc 
protecting group needs to be changed to an acetyl protecting group. This opens the 
opportunity to separate the enantiomers enzymatic using Aminoacylase. The 
heteroaromatic ring would be reduced by hydrogenation (Scheme 35).  
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Scheme 35: Retrosynthetic analysis for the unnatural arginine mimetics based on publication of P. Cali.[65] 
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2.1.3.2 Grignard Reaction 
 
To synthesise iminolate 74, tert-butylcarbazate (80) was stirred with sodiumnitrite at 0 °C. 
The produced azide was then extracted with diethylether and used directly for the second 
step. Triphenylphosphine was added to this solution and the precipitate N-Boc-
triphenyliminophosphorane (24) was obtained after filtering. 24 and diethylmesoxalate 
were refluxed in dry THF and after filtering of the side product Ph3PO the crude product 
was purified by kugelrohr distillation to give 74 as colourless oil (Scheme 36). 
 
i
ii
BocNHNH2
N
PPh3
Boc N
Boc
CO2EtEtO2C
iii
80 81 74  
Scheme 36: Reagents and conditions: (i) NaNO2, AcOH/H2O, 0 °C; (ii) PPh3, 0 °C – rt, 1.5 h, 83%; (iii) 
CO(CO2Et)2, THF, reflux, 16 h, 50%. 
 
The di-benzyl protected iodo pyrimidine 25 was synthesized using benzyl bromide and the 
strong base sodium hydride. Compound 25 and iminolate 74 were then coupled through a 
Grignard reaction with i-PrMgCl to yield 79 as yellow oil in 30% yield (Scheme 37). 
 
11 25 79
N N
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N N
NBn2
I
i N N
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CO2EtBocHN
CO2Et
ii
 
Scheme 37: Reagents and conditions: (i) NaH, BnBr, dry THF, 0 °C – rt, 19 h at rt, 78%; (ii) i-PrMgCl, dry 
THF, rt, 5 h, then iminolate 74, rt, 16 h 30%. 
 
The advantage of this reaction is that the prochiral centre can be connected directly to the 
aromatic ring system. The disadvantage is that the Grignard might also attack the nitrogen 
and the carbonyl groups of 74 which might have led to the low yield. 
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2.1.3.3 Synthesis of Racemate 
 
The plan was to remove the Boc protecting group of compound 79 with 2 M HCl in Et2O 
but because of solubility problems the Boc-group was not eliminated. With 10% TFA in 
DCM the Boc protecting group could be removed at room temperature with a yield of 96% 
(Scheme 38). 
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Scheme 38: Reagents and conditions: (i) 10% TFA in DCM, rt, 4 h, 96%; (ii) 6 M HCl/MeCN (1:1), 100 °C, 
5 h; (iii) Ac2O, Et3N, rt, 4 h, quant.; (iv) LiBr, DMF, H2O, 130 °C, 19 h, 56%. 
 
The experiment to hydrolyse the esters and decarboxylate compound 82 with 6 M 
HCl/MeCN (1:1) at 100 °C failed and destroyed the compound. So instead the amino 
group of compound 82 was first protected with an acetyl protecting group using acetic 
anhydride and triethylamine. The acetyl protecting group is an advantage for the 
enzymatic separation of the enantiomers of a racemic mixture. The enzyme Aminoacylase 
just removes the acetyl protecting group from an amino acid with the S stereocentre and 
therefore generates two separable compounds. 
To avoid the protecting group exchange from Boc-protected amine 79 to acetyl-protected 
amine 84 diethyl 2-(acetylimino)malonate (87) was synthesised (Scheme 39). 
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Scheme 39: Reagents and conditions: (i) Me2CO, 0 °C, NaN3, PPh3, rt, 40 min., 76%; (ii) dry THF, 
CO(CO2Et)2, 80 °C, 17 h, 51% (iii) dry THF, 25, i-PrMgCl, 0 °C, 3 h, 88, rt, 19 h, 7%. 
 
Acetylchloride (86) was converted with sodium azide followed by triphenylphosphine to 
give 87 in 76% yield. 87 and diethylmesoxalate were then refluxed in dry THF for 
17 hours and after filtering off the side product Ph3PO the crude product was purified by 
column chromatography to give 88 in 51% yield. Di-benzyl protected pyrimidine 
derivative 25 and malonate 88 were then coupled through a Grignard reaction with i-
PrMgCl to yield 84 in just 7% yield (Scheme 39). This is a surprising result and an 
increased yield was expected from this Grignard reaction compared to the Grignard 
coupling with malonate 74. Less side reactions have been expected because the carbon of 
the carbonyl group of the Acetyl protecting group should be less electrophilic than the 
carbon of the carbonyl group of the Boc protecting group. Compound 84 was then treated 
with lithium bromide in a H2O/DMF mixture which successfully removed one of the two 
ester groups. This resulted in amino acid 85 as a racemic mixture (Scheme 38). 
 
 
2.1.3.4 Cleavage Attempts of Benzyl Protection 
 
The next step should have been the reduction of the aromatic ring of 85 with simultaneous 
removal of the benzyl protecting groups. Pd/C and Pd(OH)2 were tried as catalyst with a 
H2-balloon (1.0 bar) in methanol, but no reaction could be observed (Scheme 40).  
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Scheme 40: Reagents and conditions: (i) Pd/C, H2-balloon (1 bar), MeOH, rt; (ii) Pd(OH)2, H2-balloon 
(1 bar), MeOH, rt. 
 
The reaction was repeated with Pd(OH)2 and the hydrogen pressure was increased to 7 bar. 
No reaction occurred and all starting material was recovered.  
 
 
2.1.3.5 Summary 
 
It is reasonable to assume that the difficulty to remove the benzyl protecting groups from 
85 will be comparably challenging as already described in the case of 44 although this 
cleavage was not investigated as thoroughly as for 44. Ultimately this synthesis was not 
quite finished due to lack of time but it would be straightforward to attempt an alternative 
synthetic strategy using PMB protection analogue to the successful synthesis of 16 and 17. 
 
 
 
2.2 Synthesis of Peptides 
 
2.2.1 Introduction 
 
The development of combinatorial chemistry facilitated the search for new drugs. The 
principle of combinatorial chemistry is the synthesis of a variety of different compounds 
under identical condition at once. The generated compound collection is called a library 
which can be screened for the desired quality.  
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Split-and-Recombine-Method 
A very elegant and efficient method to synthesise a combinatorial library is the Split-and-
Recombine-Method also called One-Bead-One-Compound-Synthesis. The method is 
based on the simultaneous synthesis of a large number of molecules on a solid phase 
(Scheme 41).  
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Scheme 41: Principle of the Split-and-Recombine-Method. 
 
Macro beads are convenient to use and are widely applied. The macro beads are equally 
divided into a series of pools. Each pool is treated with a different reagent. After the 
reaction is finished the beads are washed and excess of reagent is filtered off. The beads 
are recombined and mixed to uniformity. Then the next cycle starts and the beads are 
again split in pools. The number of different possible compounds depends on the number 
of cycles and the number of used coupling reagents. The advantage of the method is that 
each bead contains one compound and the beads can be easily separated. 
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2.2.2 Synthesis of Peptide Library 
 
The aim was to synthesise peptides with a partly stabilised α-helix structure. Oligopeptides 
are normally unfolded in aqueous solution but some peptides require a helical structure in 
the first place to bind specifically to the nucleic acid target. Different strategies have been 
developed for α-helix stabilisation in oligopeptides for example the introduction of 
covalent side chain constrains with disulfide bridges.  
One complete α-helix turn contains 3.6 amino acids where the side chains in position i and 
i + 4 locate on the same face of the α-helix. Disulfide bonds are formed via oxidation (in 
the air or with iodine) between the cysteine side chains in position i and i + 4. It is required 
to incorporation D-Cys in position i and L-Cys in position i + 4. That way the two side 
chains point towards each other and the obtained disulfide constrain has the required 
length to realise a helical loop. The full helical structure is often realised during the 
binding (Scheme 42). 
 
 
Scheme 42: Principle of obtaining α-helix loop stabilisation via disulfide bridging and realising the full 
helical structure during binding. 
 
The amino acids in position i + 2, i + 3, i + 6 and i + 7 of the α-helix are the one of interest 
for binding towards a nucleic acid target. The amino acids in these positions have been 
varied to create the peptide library (Figure 36). The chosen amino acids have a high 
propensity for binding nucleic acids (Table 11). It was also very important to create a 
library where the synthesised peptide can be identified by MALDI-ToF. The number of 
amino acids used and therefore the number of compounds finally synthesised in the library 
has been limited to achieve that. Keeping the beads in the different pools separated after 
adding the last amino acid (so the last amino acid of the peptide is known) and measuring 
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the exact mass by MALDI-ToF provides all information needed to identify each 
synthesised peptide. In the α-helix structure the amino acids in position i + 5 and i + 8 are 
not important for the binding towards the nucleic acid target and therefore the amino acid 
alanine as strong helix former has been chosen for both positions.  
 
 
Figure 36: Plot of an eight residue α-helix showing the positions of the varied amino acids in the peptide 
library in blue. Linear presentation of the peptide library peptides. 
 
To become familiar with the SPPS procedure it was decided to initially perform the 
peptide synthesis with arginine and not with the arginine mimetics (Table 11 positions 3 
and 6). This also opens the possibility to test the binding of these peptides towards the 
mRNA of TGF-β1 first and determine which peptides are strong binders. These strong 
binders can then selectively be synthesised including the arginine mimics. 
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Table 11: Shows the varying amino acids of the synthesised peptide library in blue. 
Amino Acid 
Position Library 
1 L-Cys 
2 Phe, Ile, Thr, Tyr 
3 Lys, Arg 
4 D-Cys 
5 Ala 
6 Arg, Ser 
7 Leu, Asn, Val, Tyr 
8 Ala 
 
The peptide library was synthesised by Fmoc peptide synthesis using the Mix-and-
Recombine-Method in plastic syringes with a polypropylene sinter base. Polystyrene AM 
RAM macro beads (0.50-0.56 mm, 62 nmol per bead) were swollen in NMP. For the 
Fmoc deprotection a piperidine/NMP (1:1) mixture was used for two times 10 min. The 
amino acids were coupled with PyBOP (4 eq.) and DIEA (4 eq.) for two times 60 min. 
After the penultimate amino acid the four pools kept divided to alleviate the identification 
by MALDI-ToF. 96 well-plates were used to cleave the peptide from the resin and one 
bead was added to each well. A mixture of TFA (95%), H2O (2%), m-cresol (1%) and 1, 
2-ethanedithiol (1%) was added to the wells and left for one hour.  
 
 
Figure 37: Three examples of peptides identified by MALDI-ToF. 
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Six samples from the library have been analysed by MALDI-ToF mass analysis to confirm 
if the peptide library synthesis was successful and to see if the peptides can be explicitly 
identified with this method. Three samples and their measured monoisotopic masses 
results are shown in Figure 37. 
All MALDI-ToF spectra of the samples showed a definite peak which could be identified 
as peptides from the target peptide library. 
 
 
2.2.3 Synthesis of Branched Peptides 
 
Before the products could undergo systematic ELISA screening of their binding potential 
towards the mRNA of TGF-β1 the ELISA conditions have to be tested. Therefore a 
peptide with many positive charges which will bind very well towards nucleic acid and a 
peptide with many negative charges which should not bind at all towards nucleic acid 
were synthesised by standard Fmoc methodology (Figure 38) with Rink Amide MBHA 
resin (100-200 μm, 0.34 mmol/g, 0.06 g).  
 
 
 
 
Figure 38: A: Synthesised peptide with many positive charges. B: Synthesised peptide with many negative 
charges. 
 
For the Fmoc deprotection a piperidine/NMP (1:1) mixture was used for two times 10 min. 
The amino acids up to the two times Fmoc protected Lys (to creating the branch) were 
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added with one coupling cycle of 45 min. with PyBOP (4 eq.) and DIEA (4 eq.). The 
following amino acids were added with 8 eq. of Fmoc protected amino acid, PyBOP and 
DIEA. The identity of the two peptides was confirmed by MALDI-ToF mass 
spectrometry. 
The prerequisites for a systematic ELISA screening have been created with the synthesis 
of these peptides and the peptide library. 
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3. Conclusions and Perspectives 
 
The synthesis of unnatural arginine mimetics as well as their application as building block 
in peptides to investigate binding properties towards nucleic acids are modern and exiting 
concepts in medicinal chemistry and were the subject of this thesis. 
Two different synthetic pathways towards new arginine analogues were planned and 
investigated. 
The first synthesis although overall successful was a good example for a crucial aspect of 
amino acid synthesis, the protecting group strategy. Due to the cleavage problems with the 
benzyl group on the last step the synthesis had to be restarted all over at a rather late stage 
of the project. Also noticeable is the rather surprising failure of the Negishi chemistry. 
However this was well recovered by shifting to the Heck reaction in combination with a 
successful high yielding and very stereoselective asymmetric hydrogenation. 
The second synthesis strategy required an enzymatic racemate separation as no 
straightforward conceptual alternatives had been identified while planning the synthesis. 
This synthesis shared the same problem with regard to the removal of the benzyl groups 
on the last step as already mentioned above. For timing reasons it was not possible to re-
perform the whole synthesis analogue to the first synthesis. However, it is likely that by 
applying the same slight alterations to the protection group strategy an equally satisfactory 
result can be achieved. 
Over all important synthetic concepts regarding the preparation of pyrimidine based 
arginine mimetics have been established, namely regarding stereoselectivity, C-C coupling 
chemistry and protection group considerations. With these procedures established it should 
be possible to create a larger amount of similar unnatural amino acids in relative short 
time. 
The biochemical part of the research focused on the synthesis of peptides which could be 
used to investigate the translation of mRNA of TGF-β1 into the protein by binding 
towards the mRNA. To become familiar with the SPPS procedure it was decided to 
initially perform the peptide synthesis with arginine and not with the arginine mimetics. 
The peptide library was successfully prepared by Fmoc peptide synthesis using the Mix-
and-Recombine-Method with macro beads (0.50-0.56 mm, 62 nmol per bead). Before the 
peptides could undergo systematic ELISA screening of their binding potential the ELISA 
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conditions have to be tested. Therefore a peptide as positive standard and a peptide as 
negative standard was synthesised by standard Fmoc methodology with Rink Amide 
MBHA resin.  
Thus the preconditions to perform the ELISA have been created which will facilitate 
ELISA work in future research efforts. For methodical screening peptides that show a 
positive ELISA binding response will be synthesised with a constrained arginine mimetic 
instead of the arginine. 
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4. Experimental Part 
 
 
4.1 Materials and Methods 
 
4.1.1 Chemicals 
 
Solvents 
All solvents were used as purchased from commercial suppliers. Anhydrous solvents were 
distilled from an appropriate drying agent and degassed methanol was prepared on the 
vacuum line under argon. 
 
Chemicals 
Chemicals were purchased from Acros, Aldrich, Fluka, Strem, Alfa Aesar and 
Novabiochem and were used without further purification. 
 
Phosphate Buffer (50 mM with 100 mM KCl) 
K2HPO4 (13.97 g), KH2PO4 (2.69 g) and KCl (14.91 g) were dissolved in two litre of 
distillated water. The pH was then adjusted to 7.4 with 0.1 M HCl. 
 
Triethylammonium phosphate Buffer (50 mM) 
Triethylamine (2.53 g) was added to 300 mL of distillated water. The pH was adjusted to 
3.0 with 0.1 M phosphoric acid and the volume was made up to 500 mL with distilled 
water. 
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4.1.2 Analytical Methods 
 
Thin Layer Chromatography/ Column Chromatography 
Thin Layer Chromatography (TLC) analysis was performed on Merck aluminium sheets 
with silica 60 (fluorescence marker (F254). Detection was carried out by UV (wavelength 
254 nm and 366 nm) and by staining solutions (potassium permanganate, 
cerium/molybdenium, ninhydrin). 
Preparative column chromatography was performed on Merck silica gel 60 (230 – 400 
mesh).  
 
Melting Points 
Melting points were determined on a Gallenkamp melting point apparatus and are 
uncorrected. 
 
NMR Spectroscopy 
1
H and 
13
C spectra were recorded on a Bruker DPX 400 or on a Bruker Avance 500. 
CDCl3, D2O, CD3OD, (CD3)2CO and DMSO-d6 were used as deuterated solvents. 
Chemical shifts are given in parts per million using the residual solvent peak as a 
reference. 
 
Mass Spectroscopy 
Mass spectroscopy was performed by EPSRC Mass Service Centre, Swansea University 
or by Dr. R. Jenkins, R. Hicks or D. Walker at Cardiff University. 
MALDI-ToF measurements were recorded on a Waters Micromass MALDI micro MX
TM
. 
 
IR Spectroscopy 
Infrared spectra were recorded on a FT/IR – 660 plus spectrometer operating from 4000 – 
500 cm
1
 as thin film or as KBr disk. 
 
Optical Rotation 
Optical rotations were measured on a AA-1000 polarimeter at room temperature with 
sodium D line (589 nm), c = 0.1 and L = 0.5 dm and are uncorrected. 
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X-ray Crystallography 
Crystals were grown using the Vapour Diffusion Method and measured by Dr. B. Kariuki 
at Cardiff University. 
 
HPLC  
HPLC analyses were performed on Dionex Ultimate 3000, Merck-Hitachi LaChrom L 
7000 series or Shimadzu LC10A VP. 
 
 
4.2 Procedures 
 
(S)-2-Amino-3-(2-iminohexahydropyrimidin-5-yl)propanoic acid (13) 
 
(S)-2-Amino-3-(2-aminopyrimidin-5-yl)propanoic acid (16) (0.03 g, 0.12 mmol) and 
Pd(OH)2 (0.03 g) were added in a steel autoclave. After purging with H2 water (30 mL) 
was inserted and the reaction mixture was degassed for six times. The reaction mixture 
was stirred at 15 bar of H2 at room temperature for 24 h. After releasing the H2 pressure 
the mixture was filtrated and the solvent was removed under reduced pressure to give (S)-
2-amino-3-(2-iminohexahydropyrimidin-5-yl)propanoic acid 13 (0.03 g, quantitative) as 
yellow solid. (m.p.: 68-70 °C, hygroscopic). 
 
HN
8
7 6 7
NH
89
NH
10
5
3
NH2
4
2
2 HCl
OH 1
O
 
13 
 
1
H NMR (400 MHz, D2O):  = 1.56 (1H, m, H-5), 1.71 (1H, m, H-5), 1.97 (1H, m, H-6), 
2.75 (2H, m, H-7), 3.16 (2H, m, H-7), 3.71 (1H, m, H-3) ppm; 
13
C NMR (125 MHz, 
D2O):  = 26.1 (C-6), 30.7 (C-5), 42.1 (C-7), 50.3 (C-3), 153.5 (C-9), 1651.9 (C-2) ppm; 
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ESI MS (m/z): 187 [M+H]
+
, 163, 130; HRMS (ESI): calc. for C7H15O2N4
+
 ([M+H]
+
): 
187.1190, found: 187.1188; IR (KBr disk, cm
–1
): 3368 (br), 1662, 1639, 1405, 1355, 1329, 
1300, 1174; Optical rotation: [α]D = + 26° (c = 0.1, dest. H2O). 
 
 
(S)-2-Amino-3-(2-aminopyrimidin-5-yl)propanoic acid (16) 
 
(S)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)propanoate 
(62) (0.06 g, 0.12 mmol, 1.0 eq.) was dissolved in trifluoroacetic acid (4 mL) and stirred 
for 4 h at 50 °C. The solution was washed with chloroform (2 × 4 mL) and the solvent was 
removed under reduced pressure from the water layer to give a solid. The solid was then 
refluxed in 3 M HCl (4 mL) at 110 °C for 4 h. The solvent was removed under reduced 
pressure to give (S)-2-amino-3-(2-aminopyrimidin-5-yl)propanoic acid 16 as yellow solid 
(0.03 g, 100%). (m.p.: ~ 180 °C decomp.). 
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1
H NMR (400 MHz, D2O):  = 3.02-3.15 (2H, m, H-5), 3.96-4.98 (1H, m, H-3), 8.49 (2H, 
s, H-7) ppm; 
13
C NMR (125 MHz, D2O):  = 29.2 (C-5), 53.3 (C-3), 117.7 (C-6), 155.0 
(C-8), 157.6 (C-7), 171.0 (C-2) ppm; ESI MS (m/z): 365 [2×M+H]
+
, 279, 217, 183 
[M+H]
+
, 169, 163, 149; HRMS (ESI): calc. for C7H11O2N4
+
 ([M+H]
+
): 183.0877, found: 
183.0870; IR (KBr disk, cm
–1
): 3415 (br), 3124, 3007, 2917, 2849, 1740, 1670, 1633, 
1551, 1492, 1437, 1403, 1370, 1291, 1213, 1143, 1110, 1057, 1012; Optical rotation: [α]D 
= + 48° (c = 0.1, dest. H2O). 
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(R)-2-Amino-3-(2-aminopyrimidin-5-yl)propanoic acid (17) 
 
(R)-Methyl-2-acetamido-3-(2-(bis (4-methoxybenzyl) amino) pyrimidin-5-yl) propanoate 
(63) (0.06 g, 0.12 mmol, 1.0 eq.) was dissolved in trifluoroacetic acid (4 mL) and stirred 
for 4 h at 50 °C. The solution was washed with chloroform (2 × 4 mL) and the solvent was 
removed under reduced pressure from the water layer to give a solid. The solid was then 
refluxed in 3 M HCl (4 mL) at 110 °C for 4 h. The solvent was removed under reduced 
pressure to give (S)-2-amino-3-(2-aminopyrimidin-5-yl)propanoic acid 17 as yellow solid 
(0.03 g, 100%). (m.p.: ~ 180 °C decomp.). 
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1
H NMR (400 MHz, D2O):  = 3.02-3.15 (2H, m, H-5), 3.96-4.98 (1H, m, H-3), 8.49 (2H, 
s, H-7) ppm; 
13
C NMR (125 MHz, D2O):  = 29.2 (C-5), 53.3 (C-3), 117.7 (C-6), 155.0 
(C-8), 157.6 (C-7), 171.0 (C-2) ppm; ESI MS (m/z): 365 [2×M+H]
+
, 279, 217, 183 
[M+H]
+
, 169, 163, 149; HRMS (ESI): calc. for C7H11O2N4
+
 ([M+H]
+
): 183.0877, found: 
183.0870; IR (KBr disk, cm
–1
): 3416 (br), 3127, 2917, 2849, 1740, 1670, 1633, 1551, 
1492, 1437, 1403, 1370, 1291, 1213, 1143, 1110, 1056, 1012; Optical rotation: [α]D = − 
48° (c = 0.1, dest. H2O). 
 
 
(R)-2-Amino-3-(2-iminohexahydropyrimidin-5-yl)propanoic acid (18) 
 
(R)-2-Amino-3-(2-aminopyrimidin-5-yl)propanoic acid (17) (0.03 g, 0.12 mmol) and 
Pd(OH)2 (0.03 g) were added in a steel autoclave. After purging with H2 water (30 mL) 
was inserted and the reaction mixture was degassed for six times. The reaction mixture 
was stirred at 15 bar of H2 at room temperature for 24 h. After releasing the H2 pressure 
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the mixture was filtrated and the solvent was removed under reduced pressure to give (R)-
2-amino-3-(2-iminohexahydropyrimidin-5-yl)propanoic acid 18 (0.03 g, quantitative) as 
yellow solid. (m.p.: 68-70 °C, hygroscopic). 
 
HN
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NH
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18 
 
1
H NMR (400 MHz, D2O):  = 1.56 (1H, m, H-5), 1.71 (1H, m, H-5), 1.96 (1H, m, H-6), 
2.75 (2H, m, H-7), 3.16 (2H, m, H-7), 3.70 (1H, m, H-3) ppm; 
13
C NMR (125 MHz, 
D2O):  = 26.2 (C-6), 30.7 (C-5), 42.2 (C-7), 50.3 (C-3), 153.5 (C-9), 1651.9 (C-2) ppm; 
ESI MS (m/z): 187 [M+H]
+
, 163, 130; HRMS (ESI): calc. for C7H15O2N4
+
 ([M+H]
+
): 
187.1190, found: 187.1188; IR (KBr disk, cm
–1
): 3368 (br), 1662, 1639, 1405, 1355, 1329, 
1300, 1174; Optical rotation: [α]D = − 26° (c = 0.1, dest. H2O). 
 
 
N, N-Dibenzyl-5-iodopyrimidin-2-amine (25)  
 
Under nitrogen atmosphere sodium hydride (0.03 g, 0.73 mmol, 3.2 eq., 60% NaH in oil) 
was added to a solution of 2-amino-5-iodopyrimidine (0.05 g, 0.23 mmol, 1.0 eq.) in dry 
THF (1 mL) at 0 °C. Benzyl bromide (0.07 mL, 0.58 mmol, 2.5 eq.) was added at 0 °C 
after 30 min. and the reaction mixture was then allowed to warm up to room temperature. 
After 19 h water (3 mL) and ethyl acetate (2 mL) were added and the water phase was 
washed with ethyl acetate (3 mL). The combined organic phase was washed with brine 
(5 mL), dried over Na2SO4, filtered and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography (hexane to hexane/ethyl 
acetate, 10:1, Rf = 0.57) to give N, N-dibenzyl-5-iodopyrimidin-2-amine 25 (0.07 g, 78%) 
as a colourless solid. (m.p.: 117 °C). 
 
Chapter 4     Experimental Part 
81 
 
 
25 
 
1
H NMR (500 MHz, CDCl3):  = 4.74 (4H, s, H-4), 7.24-7.13 (10H, m, H-Ar), 8.35 (2H, 
s, H-2) ppm; 
13
C NMR (125 MHz, CDCl3):  = 48.5 (C-4), 75.8 (C-1), 127.7 (C-8), 127.9 
(C-6), 128.7 (C-7), 137.9 (C-5), 160.7 (C-3), 162.8 (C-2) ppm; EI MS (m/z): 401 [M]
+
, 
311, 232, 204, 184, 91; HRMS (EI): calc. for C18H16IN3
· +
 ([M]
+
): 401.0383, found: 
401.0376; IR (thin film, cm
–1
): 1570, 1512, 1426, 1393, 1362, 930. 
 
 
N, N-Di-tert-butoxycarbonyl-5-iodopyrimidin-2-amine (32) 
 
2-Amino-5-iodopyrimidine (1.0 g, 4.52 mmol, 1.0 eq.), di-tert-butyldicarbonate (2.39 g, 
10.9 mmol, 2.4 eq.) and 4-dimethylaminopyridine (0.14 g, 1.15 mmol, 0.26 eq.) were 
dissolved in THF (50 mL) and then refluxed at 80 C for 24 h. The solvent was removed 
under reduced pressure and the brown solid was purified via column chromatography 
(hexane/ethyl acetate, 3:1, Rf = 0.60) to give N, N-di-tert-butoxycarbonyl-5-
iodopyrimidin-2-amine 32 (1.85 g, 97%) as a colourless solid. (m.p.: 147 °C). 
 
 
32 
 
1
H NMR (500 MHz, CDCl3):  = 0.47 (18H, s, H-6), 8.90 (2H, s, H-2) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 27.8 (C-6), 83.9 (C-5), 89.7 (C-1), 150.4 (C-4), 157.5 (C-3), 
164.0 (C-2) ppm; EI MS (m/z): 421 [M]
+
, 321, 277, 247, 221, 57; HRMS (ESI): calc. for 
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C14H21O4N3I1
+
 ([MH]+): 422.0571, found: 422.0569; IR (thin film, cm–1): 3425 (br, O-
H), 2983 (C-H), 1797, 1761 (C=O), 1541, 1422, 1370, 1291. 
 
 
(Z)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylate (37) 
 
N, N-Dibenzyl-5-iodopyrimidin-2-amine (25) (0.080 g, 0.20 mmol, 1.0 eq.), methyl-2-
acet-amidoacrylate (0.037 g, 0.26 mmol, 1.3 eq.), NaHCO3 (0.034 g, 0.40 mmol, 2.0 eq.), 
Bu4NCl (0.068 g, 0.24 mmol, 1.2 eq.), PdCl2 (0.005 g, 0.03 mmol, 15 mol%) and tri-o-
tolylphosphine (0.009 g, 0.03 mmol, 15 mol%) were mixed with DMF (anhydrous, 2 mL) 
and stirred for 4 h at 100 °C under nitrogen. The reaction was quenched with brine 
(15 mL) and ethyl acetate (15 mL) was added. The org. layer was separated, washed with 
brine (2 × 15 mL), dried over MgSO4 and filtered. The solvent was removed under 
reduced pressure and the brown solid was purified via column chromatography 
(hexane/ethyl acetate, 1:1, Rf = 0.18) to give (Z)-methyl-2-acetamido-3-(2-
(dibenzylamino)pyrimidin-5-yl)acrylate 37 (0.065 g, 80%) as a colourless solid. (m.p.: 
160 °C). 
 
 
37 
 
1
H NMR (500 MHz, CD3OD):  = 2.12 (3H, s, H-6), 3.81 (3H, s, H-1), 4.89 (4H, s, H-11), 
7.18-7.34 (10H, m, H-13, H-14, H-15), 7.35 (1H, s, H-7), 8.61 (2H, s, H-9) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 23.5 (C-6), 49.1 (C-11), 52.6 (C-1), 116.8 (C-8), 120.8 (C-
3), 127.2 (C-15), 127.5 (C-13), 128.1 (C-7), 128.5 (C-14), 137.4 (C-12), 159.6 (C-9), 
161.4 (C-10), 165.7 (C-2), 168.8 (C-5) ppm; ESI MS (m/z): 417 [M+H]
+
, 375, 325, 283, 
144, 129; HRMS (ESI): calc. for C24H25O3N4
+
 ([MH]+): 417.1921, found: 417.1921; IR 
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(KBr disk, cm
–1
): 3274, 3027, 2952, 2901, 2845, 1720, 1670, 1598, 1523, 1453, 1427, 
1402, 1358, 1239, 1211, 1189, 1147, 1112, 1029. 
 
 
(Z)-Methyl-2-(tert-butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-
yl)acrylate (38) 
 
N, N-Dibenzyl-5-iodopyrimidin-2-amine (25) (0.50 g, 1.25 mmol, 1.0 eq.), methyl-2-(tert-
butoxycarbonylamino)acrylate (0.33 g, 1.62 mmol, 1.3 eq.), NaHCO3 (0.21 g, 2.50 mmol, 
2.0 eq.), Bu4NCl (0.45 g, 1.62 mmol, 1.3 eq.), PdCl2 (0.06 g, 0.25 mmol, 20 mol%) and 
tri-o-tolylphosphine (0.08 g, 0.25 mmol, 20 mol%) were mixed with DMF (anhydrous, 
4 mL) and stirred for 19 h at 70 °C under nitrogen. The reaction was quenched with 
sat. aq. NaHCO3-solution (20 mL) and ethyl acetate (20 mL) was added. The org. layer 
was separated, washed with water (2 × 20 mL), dried over MgSO4 and filtered. The 
solvent was removed under reduced pressure and the brown solid was purified via column 
chromatography (hexane/ethyl acetate, 5:1, Rf = 0.26) to give (Z)-methyl-2-(tert-butoxy-
carbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylate 38 (0.415 g, 70%) as a light 
yellow solid. (m.p.: 122 °C). 
 
 
38 
 
1
H NMR (500 MHz, CDCl3):  = 1.38 (9H, s, H-7), 3.77 (3H, s, H-1), 4.81 (4H, s, H-12), 
7.11 (1H, s, H-3), 7.14-7.26 (10H, m, H-14, H-15, H-16), 8.49 (2H, s, H-10) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 21.2 (C-7), 49.5 (C-12), 52.8 (C-1), 81.4 (C-6), 117.5 (C-9), 
122.1 (C-3), 126.7 (C-8), 127.3 (C-16), 127.9 (C-14), 128.7 (C-15), 137.9 (C-13), 153.0 
(C-5), 159.6 (C-10), 161.6 (C-11), 166.1 (C-2) ppm; ESI MS (m/z): 949 [2×M+H]
+
, 748, 
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497, 475 [M+H]
+
, 419; HRMS (ESI): calc. for C27H31O4N4
+
 ([MH]+): 475.2340, found: 
475.2332; IR (KBr disk, cm
–1
): 3314, 3027, 2977, 2947, 1720, 1696, 1637, 1598, 1519, 
1492, 1454, 1438, 1392, 1360, 1303, 1230, 1161. 
 
 
(Z)-Methyl-3-(2-(bis(tert-butoxycarbonyl)-amino)pyrimidin-5-yl)-2-(tert-
butoxycarbonylamino)acrylate (39) 
 
N, N-Dibenzyl-5-iodopyrimidin-2-amine (25) (0.53 g, 1.25 mmol, 1.0 eq.), methyl-2-(tert-
butoxycarbonylamino)acrylate (0.36 g, 1.80 mmol, 1.4 eq.), NaHCO3 (0.21 g, 2.50 mmol; 
2.0 eq.), Bu4NCl (0.45 g, 1.62 mmol, 1.3 eq.), PdCl2 (0.06 g, 0.25 mmol, 20 mol%) and 
tri-o-tolylphosphine (0.08 g, 0.25 mmol, 20 mol%) were mixed with DMF (anhydrous, 
6 mL) and stirred for 19 h at 70 °C under nitrogen. The reaction was quenched with 
sat. aq. NaHCO3-solution (20 mL) and ethyl acetate (20 mL) was added. The org. layer 
was separated, washed with water (2 × 20 mL), dried over MgSO4 and filtered. The 
solvent was removed under reduced pressure and the brown solid was purified via column 
chromatography (hexane/ethyl acetate, 3:1, Rf = 0.26) to give (Z)-methyl-3-(2-(bis(tert-
butoxycarbonyl)-amino)pyrimidin-5-yl)-2-(tert-butoxycarbonylamino)acrylate 39 (0.19 g, 
30%) as a colourless solid. (m.p.: 143 °C). 
 
 
39 
 
1
H NMR (500 MHz, CDCl3):  = 1.44 (27H, s, H-7, H-14), 3.89 (3H, s, H-1), 6.74 (1H, s, 
H-4), 7.14 (1H, s, H-8) ppm; 
13
C NMR (125 MHz, CDCl3):  = 27.8 (C-14), 28.1 (C-7), 
53.1 (C-1), 81.9 (C-6), 83.5 (C-13), 120.2, 126.7, 126.9, 150.3 (C-12), 152.0 (C-5), 157.2 
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(C-11), 158.4 (C-10), 165.0 (C-2) ppm; ESI MS (m/z): 989 [2×M+H]
+
, 495 [M+H]
+
, 395, 
321, 265; HRMS (ESI): calc. for C23H35O8N4
+
 ([M+H]
+
): 495.2449, found:. 495.2454; IR 
(KBr disk, cm
–1
): 3355, 2980, 2932, 1799, 1719, 1651, 1578, 1550, 1504, 1432, 1368, 
1281, 1162, 1106. 
 
 
(Z)-2-(tert-Butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylic acid 
(43) 
 
(Z)-Methyl-2-(tert-butoxy-carbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)acryl-ate 
(38) (0.15 g, 0.32 mmol, 1.0 eq.) and lithium hydroxide monohydrate (0.07 g, 0.95 mmol, 
3.0 eq.) were dissolved in a mixture of MeOH (8 mL), THF (4 mL) and water (1 mL). The 
solution was stirred for 27 h at room temperature, diluted with ethyl acetate (40 mL) and 
washed with 1 M HCl (40 mL). The org. phase was separated, dried with MgSO4 and 
filtered. The solvent was removed under reduced pressure to give a light yellow solid of 
(Z)-2-(tert-butoxycarbonylamino)-3-(2-(dibenzyl-amino)pyrimidin-5-yl)acrylic acid 43 
(0.14 g, 95%). (m.p.: 143-146 °C). 
 
 
43 
 
1
H NMR (500 MHz, CDCl3):  = 1.37 (3H, s, H-7), 4.83 (4H, s, H-12), 6.41 (1H, s, H-4), 
7.11-7.33 (10H, m, H-14, H-15, H-16), 8.55 (2H, s, H-10), 9.40 (1H, s, H-1) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 28.0 (C-7), 49.4 (C-12), 81.2 (C-6), 117.3 (C-9), 122.2 (C-
3), 126.6 (C-8), 127.2 (C-14), 127.5 (C-16), 128.5 (C-15), 137.0 (C-13), 153.0 (C-5), 
159.2 (C-10), 160.4 (C-11), 169.0 (C-2) ppm; ESI MS (m/z): 921 [2×M+H]
+
, 461 [M+H]
+
, 
405; HRMS (ESI): calc. for C26H29O4N4
+
 ([MH]+): 461.2183, found: 461.2176; IR (KBr 
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disk, cm
–1
): 3322, 3061, 3028, 2979, 2929, 2627 (br), 1702, 1636, 1596, 1519, 1453, 1423, 
1393, 1358, 1235, 1159. 
 
 
(S)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoate (44) 
 
(Z)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylate (37) (3.01 g, 7.23 
mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate (0.06 g, 0.15 mmol, 
2 mol%) and (S,S)-Me-DUPHOS (0.09 g, 0.29 mmol, 4 mol%) were added to a steel 
autoclave. After purging two times with H2, degassed MeOH (30 mL) was inserted and the 
reaction mixture was degassed again three times. The reaction was stirred at room 
temperature with 35 bar of H2 for 24 h and stopped via release of H2 pressure. After 
filtration through Celite the crude oil was purified via column chromatography 
(hexane/ethyl acetate, 1:2, Rf = 0.33) to give (S)-methyl-2-acetamido-3-(2-
(dibenzylamino)pyrimidin-5-yl)propanoate 44 (2.82 g, 93%) as a colourless solid. (m.p.: 
123 °C). 
 
 
44 
 
1
H NMR (500 MHz, CDCl3):  = 1.95 (3H, s, H-6), 2.85-2.96 (2H, m, H-7), 3.68 (3H, s, 
H-1), 4.70-4.78 (5H, m, H-3, H-11), 6.09 (1H, d,
 3
JHH = 7.2 Hz, H-4), 7.09-7.26 (10H, m, 
H-13, H-14, H-15), 8.03 (2H, s, H-9) ppm; 
13
C NMR (125 MHz, CDCl3):  = 23.2 (C-6), 
31.9 (C-7), 49.1 (C-11), 52.6 (C-1), 53.1 (C-3), 116.9 (C-8), 127.1 (C-15), 127.6 (C-13), 
128.1 (C-14), 138.1 (C-12), 158.4 (C-9), 161.7 (C-10), 169.7 (C-5), 171.8 (C-2) ppm; ESI 
MS (m/z): 419 [M+H]
+
, 417, 276, 217, 129, 102, 74; HRMS (ESI): calc. for C24H27O3N4
+
 
([MH]+): 419.2078, found: 419.2077; IR (KBr disk, cm–1): 3297, 3061, 3026, 2921, 
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2851, 1948, 1746, 1654, 1609, 1541, 1509, 1452, 1429, 1403, 1359, 1259, 1228, 1202, 
1169, 1120, 1028; Enantiomeric excess (ee): 98 % [HPLC: ODH column, 25 °C, hexane/i-
PrOH: 20/80, 1 mL/min., ret. times: 10.1 min. (minor), 19.3 min. (major)]; Optical 
rotation: [α]D = +80°(c = 0.1, CH2Cl2). 
 
 
(R)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoate (45) 
 
(Z)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylate (37) (0.30 g, 
0.720 mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate (0.006 g, 
0.015 mmol, 2 mol%) and (R,R)-Me-DUPHOS (0.009 g, 0.029 mmol, 4 mol%) were 
added to a steel autoclave. After purging two times with H2, degassed MeOH (30 mL) was 
inserted and the reaction mixture was degassed again three times. The reaction was stirred 
at room temperature with 35 bar of H2 for 24 h and stopped via release of H2 pressure. 
After filtration through Celite the crude oil was purified via column chromatography 
(hexane/ethyl acetate, 1:2, Rf = 0.33) to give (R)-methyl-2-acetamido-3-(2-
(dibenzylamino)pyrimidin-5-yl)propanoate 45 (0.28 g, 93%) as a colourless solid. (m.p.: 
123 °C). 
 
 
45 
 
1
H NMR (500 MHz, CDCl3):  = 1.97 (3H, s, H-6), 2.86-2.97 (2H, m, H-7), 3.70 (3H, s, 
H-1), 4.74-4.78 (5H, m, H-3, H-11), 6.06 (1H, d,
 3
JHH = 7.3 Hz, H-4), 7.12-7.26 (10H, m, 
H-13, H-14, H-15), 8.02 (2H, s, H-9) ppm; 
13
C NMR (125 MHz, CDCl3):  = 23.2 (C-6), 
31.8 (C-7), 49.1 (C-11), 52.6 (C-1), 53.0 (C-3), 116.8 (C-8), 127.1 (C-15), 127.5 (C-13), 
128.5 (C-14), 138.1 (C-12), 158.4 (C-9), 161.8 (C-10), 169.7 (C-5), 171.8 (C-2) ppm; ESI 
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MS (m/z): 419 [M+H]
+
, 441; HRMS (ESI): calc. for C24H27O3N4
+
 ([MH]+): 419.2078, 
found: 419.2076.IR (KBr disk, cm
–1
): 3296, 3064, 3025, 2916, 2849, 1938, 1746, 1653, 
1610, 1541, 1510, 1452, 1430, 1404, 1360, 1261, 1230, 1201, 1168, 1117, 1029; 
Enantiomeric excess (ee): 99 % [HPLC: ODH column, 25 °C, hexane/i-PrOH: 20/80, 
1 mL/min., ret. times: 10.1 min. (major), 19.3 min. (minor)]; Optical rotation: [α]D = −80° 
(c = 0.1, CH2Cl2). 
 
 
(S)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride (46) 
 
3 M HCl (20 mL) was added to a solution of (S)-methyl 2-acetamido-3-(2-(dibenzyl-
amino)pyrimidin-5-yl)propanoate (44) (0.235 g, 0.56 mmol) in acetone (0.5 mL). The 
solution was refluxed at 110 °C for 6 h. After room temperature was reached the solvent 
was removed under reduced pressure to yield (S)-1-carboxy-2-(2-
(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride 46 (0.22 g, 98%) as light yellow 
solid. (Rf = 0.56 (ethanol/ acetic acid, 80:20); m.p.: 143 – 146 °C) 
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46 
 
1
H NMR (500 MHz, MeOD):  = 3.20-3.41 (2H, m, H-5), 4.41 (1H, t, 3JHH = 7.3 Hz, H-3), 
5.00 (4H, s, H-9), 7.23-7.40 (10H, m, H-11, H-12, H-13), 8.63 (2H, s, H-7) ppm; 
13
C 
NMR (125 MHz, MeOD):  = 29.0 (C-5), 55.4 (C-9), 52.5 (C-3), 117.2 (C-6), 127.2 (C-
11), 127.5 (C-13), 128.3 (C-12), 134.8 (C-10), 155.3 (C-7), 157.6 (C-8), 169.0 (C-2) ppm; 
ESI MS (m/z): 725 [2×M-Cl]
+
, 421, 363 [M-Cl]
+
, 290; HRMS (ESI): calc. for 
C21H23O2N4
+
 ([M-Cl]
+
): 363.1816, found: 363.1819; IR (KBr disk, cm
–1
): 3397 (br), 2928 
(br), 1963 (br), 1735, 1647, 1613, 1584, 1545, 1496, 1453, 1410, 1352, 1207, 1079, 1027. 
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(R)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride (47) 
 
3 M HCl (20 mL) was added to a solution of (45) (R)-methyl-2-acetamido-3-(2-
(dibenzylamino)-pyrimidin-5-yl)propanoate (0.2 g, 0.49 mmol) in acetone (1 mL). The 
solution was refluxed at 110 °C for 6 h. After room temperature was reached the solvent 
was removed under reduced pressure to yield (R)-1-carboxy-2-(2-
(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride 47 (0.2 g, 102%) as light yellow 
solid. (Rf = 0.56 (ethanol/ acetic acid, 80:20); m.p.: 143 – 146 °C) 
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47 
 
1
H NMR (500 MHz, MeOD):  = 3.20-3.42 (2H, m, H-5), 4.40 (1H, t, 3JHH = 7.3 Hz, H-3), 
5.01 (4H, s, H-9), 7.21-7.40 (10H, m, H-11, H-12, H-13), 8.63 (2H, s, H-7) ppm; 
13
C 
NMR (125 MHz, MeOD):  = 29.0 (C-5), 55.3 (C-9), 52.5 (C-3), 117.1 (C-6), 127.2 (C-
11), 127.5 (C-13), 128.2 (C-12), 134.8 (C-10), 155.3 (C-7), 157.5 (C-8), 169.0 (C-2) ppm; 
ESI MS (m/z): 725 [2×M-Cl]
+
, 421, 363 [M-Cl]
+
, 290; HRMS (ESI): calc. for 
C21H23O2N4
+
 ([M-Cl]
+
): 363.1816, found: 363.1819; IR (KBr disk, cm
–1
): 3400 (br), 2925 
(br), 2349, 1964 (br), 1740, 1646, 1612, 1543, 1496, 1453, 1137, 1080, 1027. 
 
 
(S)-2-(5-((S)-1-Amino-1-oxopropan-2-ylamino)-2,4-dinitrophenylamino)-3-(2-(di-
benzylamino)pyrimidin-5-yl)propanoic acid (48) 
 
(S)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride 46 (0.06 g, 
0.16 mmol, 1.0 eq.), N-(2,4)-dinitro-5-fluorophenyl)-L-alanine amide (FDAA) (0.05 g, 
0.17 mmol, 1.1 eq.) and Cs2CO3 (0.99 g, 3.04 mmol, 20 eq.) were dissolved in a 1:1 
mixture of acetone and water (2 mL). The reaction was protected with aluminium foil and 
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stirred at 40 C for two hours. The solvent was removed under reduced pressure and the 
resulting orange solid was used crude for the HPLC experiments. 
 
 
48 
 
Enantiomeric excess (ee): 96 % [HPLC: C18 reverse phase column, 100% TEAP-buffer to 
100% MeCN, 1 mL/min., ret. times: 26.1 min. (major), 27.3 min. (minor)]. 
 
 
(R)-2-(5-((S)-1-Amino-1-oxopropan-2-ylamino)-2,4-dinitrophenylamino)-3-(2-(di-
benzylamino)pyrimidin-5-yl)propanoic acid (49) 
 
(R)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride 47 (0.01 g, 
0.025 mmol, 1.0 eq.), N-(2,4)-dinitro-5-fluorophenyl)-L-alanine amide (FDAA) (0.007 g, 
0.027 mmol, 1.1 eq.) and Cs2CO3 (0.164 g, 0.50 mmol, 20 eq.) were dissolved in a 1:1 
mixture of acetone and water (2 mL). The flask was wrapped in aluminium foil to exclude 
light and stirred at 40 C for two hours. The solvent was removed under reduced pressure 
and the resulting orange solid was used crude for the HPLC experiments. 
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49 
 
Enantiomeric excess (ee): 98 % [HPLC: C18 reverse phase column, 100% TEAP-buffer to 
100% MeCN, 1 mL/min., ret. times: 26.1 min. (minor), 27.3 min. (major)]. 
 
 
(1S)-1-Carboxy-2-(2-(dibenzylamino)-1,4,5,6-tetrahydropyrimidin-5-yl)ethanamin-
ium chloride (50) 
 
(S)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride (46) (0.06 g, 
0.15 mmol) and Pd(OH)2 (0.04 g) were added in a steel autoclave. After purging with H2 
degassed MeOH (30 mL) was inserted and the reaction mixture was degassed again for 
three times. The reaction mixture was stirred at 15 bar of H2 at room temperature for 24 h. 
After releasing the H2 pressure the mixture was filtrated through Celite and the solvent 
was removed under reduced pressure to give (1S)-1-carboxy-2-(2-(dibenzylamino)-
1,4,5,6-tetrahydropyrimidine-5-yl)ethanaminium chloride 50 (0.06 g, 99%) as yellow 
solid. (Rf = 0.24 (ethanol/ acetic acid, 80:20); m.p.: 123 - 125 C). 
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50 
 
1
H NMR (400 MHz, D2O):  = 1.70-1.92 (2H, m, H-5), 2.07-2.23 (1H, m, H-6), 3.00-3.49 
(4H, s, H-7), 3.74 (1H, t,
 3
JHH = 7.3 Hz, H-3), 4.53 (4H, s, H-10), 7.14-7.40 (10H, m, H-
12, H-13, H-14), 8.07 (2H, s, H-9) ppm; 
13
C NMR (125 MHz, MeOD):  = 26.0 (C-6), 
31.0 (C-5), 43.1 (C-7), 51.3 (C-10), 52.1 (C-3), 126.7 (C-12), 128.1 (C-14), 129.1 (C-13), 
135.0 (C-11), 144.3 (C-9), 164.7 (C-2) ppm.ESI MS (m/z): 733 [2×M-Cl]
+
, 423, 367 [M-
Cl]
+
, 294; HRMS (ESI): calc. for C21H27O2N4
+
 ([M-Cl]
+
): 367.2129, found: 367.2128; IR 
(KBr disk, cm
–1
): 3382 (br), 3237 (br), 3031, 2922, 1623, 1496, 1453, 1422, 1079, 1028. 
 
 
(1S)-1-Carboxy-2-(2-(dibenzylamino)-1,4,5,6-tetrahydropyrimidin-5-yl)ethanamin-
ium chloride (51) 
 
(S)-1-Carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethanaminium chloride (47) (0.06 g, 
0.15 mmol) and Pd(OH)2 (0.04 g) were added in a steel autoclave. After purging with H2 
degassed MeOH (30 mL) was inserted and the reaction mixture was degassed again for 
three times. The reaction mixture was stirred at 30 bar of H2 at room temperature for 24 h. 
After releasing the H2 pressure the mixture was filtrated through Celite and the solvent 
was removed under reduced pressure to give (1S)-1-carboxy-2-(2-(dibenzylamino)-
1,4,5,6-tetrahydropyrimidine-5-yl)ethanaminium chloride 51 (0.06 g, 99%) as yellow 
solid. (Rf = 0.24 (ethanol/ acetic acid, 80:20); m.p.: 123 - 125 C). 
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51 
 
1
H NMR (400 MHz, D2O):  = 1.71-1.94 (2H, m, H-5), 2.06-2.23 (1H, m, H-6), 3.02-3.48 
(4H, s, H-7), 3.75 (1H, t,
 3
JHH = 7.3 Hz, H-3), 4.53 (4H, s, H-10), 7.14-7.41 (10H, m, H-
12, H-13, H-14), 8.07 (2H, s, H-9) ppm; 
13
C NMR (125 MHz, MeOD):  = 26.1 (C-6), 
31.0 (C-5), 43.1 (C-7), 51.2 (C-10), 52.2 (C-3), 126.7 (C-12), 128.0 (C-14), 129.1 (C-13), 
135.0 (C-11), 144.3 (C-9), 164.7 (C-2) ppm.ESI MS (m/z): 733 [2×M-Cl]
+
, 423, 367 [M-
Cl]
+
, 294; HRMS (ESI): calc. for C21H27O2N4
+
 ([M-Cl]
+
): 367.2129, found: 367.2128; IR 
(KBr disk, cm
–1
): 3382 (br), 3237 (br), 3033, 2921, 1623, 1496, 1454, 1422, 1078, 1028. 
 
 
(S)-5-(2-Acetamido-2-carboxyethyl)-2-aminopyrimidin-1-ium nitrate (56) 
 
(S)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoate 44 (0.11 g, 
0.26 mmol, 1.0 eq.) and ammoniumcerium(IV)nitrate (0.83 g, 1.51 mmol, 6.0 eq.) were 
dissolved in a 9:1 mixture of acetonitrile and water (10 mL) and stirred for 6 ½ h at room 
temperature. The acetonitrile was removed under reduced pressure and the cerium salt was 
precipitated from the water by changing the pH from one to twelve with 3 M NaOH. The 
solid was filtered off and washed with ethyl acetate (10 mL). The water layer was 
separated and the solvent was removed under reduced pressure to give a light yellow solid. 
MeOH (15 mL) was added to the solid and the solvent was removed from the filtrate to 
yield (S)-5-(2-acetamido-2-carboxyethyl)-2-aminopyrimidin-1-ium nitrate 56 (0.07 g, 
92%) as yellow solid. (m.p.: ~ 150 °C decomp.) 
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56 
 
1
H NMR (500 MHz, MeOD):  = 1.94 (3H, s, H-5), 2.75-2.83 (1H, dd, 3JHH = 4.8 Hz, 9.0 
Hz, H-6), 2.98-3.05 (1H, dd, 
3
JHH = 4.8 Hz, 9.0 Hz, H-6), 4.36-4.39 (1H, dd, 
3
JHH = 4.8 
Hz, 2.2 Hz, H-2), 8.12 (2H, s, H-8) ppm; 
13
C NMR (125 MHz, MeOD):  = 23.7 (C-5), 
33.3 (C-6), 57.0 (C-2) 120.7 (C-7), 158.5 (C-8), 171.1 (C-9), 176.0 (C-4), 187.2 (C-1) 
ppm; IR (KBr disk, cm
–1
): 3442 (br), 2963, 2931, 2857, 2426 (br), 1789, 1715 (C=O), 
1642 (C=O), 1567 (N-O asym), 1385 (N-O sym), 1208, 1145, 1112, 1049. 
 
 
5-Iodo-N, N-bis(4-methoxybenzyl)pyrimidin-2-amine (60) 
 
2-Amino-5-iodopyrimidine (1.00 g, 4.5 mmol, 1.0 eq.) and sodium hydride (0.54 g, 
13.8 mmol, 3.0 eq., 60% NaH in oil) were mixed with dry THF (40 mL). 4-
Methoxybenzyl chloride (3.1 mL, 22.8 mmol, 5.0 eq.) was added at 0 °C and the reaction 
mixture was then stirred at 30 °C for 23 h. The reaction was quenched with water (20 mL) 
and ethyl acetate (20 mL). The water layer was washed with ethyl acetate (2 × 10 mL) and 
the combined org. layer was dried over MgSO4 and filtered. The crude product was 
purified via column chromatography (hexane/ethyl acetate, 20:1 to 10:1, Rf = 0.33 for 
10:1) to give 5-iodo-N, N-bis(4-methoxybenzyl)pyrimidin-2-amine 60 (1.90 g, 91%) as a 
colourless solid. (m.p.: 80-81 °C). 
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60 
 
1
H NMR (400 MHz, CDCl3):  = 3.80 (6H, s, H-9), 4.72 (4H, s, H-4), 6.84 (4H, d,
 
3
JHH = 8.7 Hz, H-7), 7.15 (4H, d,
 3
JHH = 8.7 Hz, H-6), 8.43 (2H, s, H-2) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 48.4 (C-4), 55.3 (C-9), 75.4 (C-1), 113.9 (C-7), 128.9 (C-6), 
129.8 (C-5), 158.8 (C-8), 160.4 (C-3), 162.6 (C-2) ppm; ESI MS (m/z): 500 [M+NH4]
+
, 
462 [M+H]
+
, 419, 391, 276, 199, 137; HRMS (ESI): calc. for C20H21O2IN3
+
 ([M+H]
+
): 
462.0673, found: 462.0671; IR (thin film, cm
–1
): 3008 (m) , 2954 (w), 2934 (w), 2910 (w), 
2835 (m), 1612 (m), 1569 (s), 1512 (s), 1464 (w), 1418 (w), 1392 (m), 1359 (m), 1303 
(m), 1248 (s), 1174 (m), 1109 (w), 1036 (m). 
 
 
(Z)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)acrylate 
(61) 
 
5-Iodo-N, N-bis(4-methoxybenzyl)pyrimidin-2-amine (60) (0.289 g, 0.63 mmol, 1.0 eq.), 
methyl-2-acet-amidoacrylate (0.100 g, 0.70 mmol, 1.1 eq.), NaHCO3 (0.106 g, 1.26 mmol, 
2.0 eq.), Bu4NCl (0.211 g, 0.76 mmol, 1.2 eq.), PdCl2 (0.023 g, 0.13 mmol, 20 mol%) and 
tri-o-tolylphosphine (0.077 g, 0.25 mmol, 40 mol%) were mixed with DMF (anhydrous, 
12 mL) and stirred for 24 h at 110 °C under nitrogen. The reaction was quenched with 
ethyl acetate (12 mL) and washed with water (3 × 15 mL). The combined water layer was 
washed with ethyl acetate (12 mL). The combined org. layer was dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The crude product was 
purified via column chromatography (hexane/ethyl acetate, 1:2, Rf = 0.47) to give (Z)-
methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)-pyrimidin-5-yl)acrylate 61 
(0.130 g, 43%) as a colourless solid. (m.p.: 172 - 173 °C). 
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61 
 
1
H NMR (400 MHz, CDCl3):  = 2.17 (3H, s, H-6), 3.79 (4H, s, H-16), 3.83 (3H, s, H-1), 
4.78 (4H, s, H-11), 6.83 (4H, d, J = 8.6 Hz, H-14), 7.14 (4H, d, J = 8.6 Hz, H-13), 7.27 
(1H, s, H-4), 7.30 (1H, s, H-7), 8.46 (2H, s, H-9) ppm; 
13
C NMR (125 MHz, 
CDCl3):  = 23.6 (C-7), 48.2 (C-11), 52.6 (C-1), 55.2 (C-16), 113.9 (C-14), 116.7 (C-8), 
120.4 (C-3), 128.1 (C-7), 128.9 (C-13), 129.5 (C-12), 158.9 (C-15), 159.6 (C-9), 161.3 (C-
10), 165.8 (C-2), 168.6 (C-5) ppm; ESI MS (m/z): 975 [2×M+Na]
+
, 953 [2×M+H]
+
, 499 
[M+Na]
+
,477 [M+H]
+
,462, 279, 163; HRMS (ESI): calc. for C26H29O5N4
+
 ([MH]+): 
477.2132, found: 477.2124; IR (thin film, cm
–1
): 3371 (br), 2957, 2920, 1715, 1665, 1595, 
1511, 1435, 1359, 1246, 1174, 1111, 1036. 
 
 
(S)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)propan-
oate (62) 
 
(Z)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)acrylate (61) 
(0.50 g, 1.05 mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate (0.018 g, 
0.044 mmol, 4 mol%) and (S,S)-Me-DUPHOS (0.085 g, 0.085 mmol, 8 mol%) were added 
in a steel autoclave. After purging with H2 two times degassed MeOH (30 mL) was 
inserted and the reaction mixture was degassed again for three times. The reaction was 
stirred at room temperature with 38 bar of H2 for 24 h and stopped via release of H2 
pressure. After filtration through Celite the crude oil was purified via column 
chromatography (hexane/ethyl acetate, 1:2, Rf = 0.29) to give (S)-methyl-2-acetamido-3-
(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)propanoate 62 (0.45 g, 90%) as a 
colourless solid. (m.p.: 66-68 °C). 
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62 
 
1
H NMR (400 MHz, CDCl3):  = 2.04 (3H, s, H-6), 2.90-3.08 (2H, m, H-7), 3.78 (3H, s, 
H-1), 3.79 (6H, s, H-16), 4.74 (4H, s, H-11), 4.81-4.87 (1H, m, H-3), 6.09 (1H, d,
 
J = 7.4 
Hz, H-4), 6.83 (4H, d,
 3
JHH = 8.7 Hz, H-14), 7.14 (4H, d,
 3
JHH = 8.7 Hz, H-13), 8.09 (2H, s, 
H-9) ppm; 
13
C NMR (125 MHz, CDCl3):  = 23.2 (C-6), 31.8 (C-7), 48.1 (C-11), 52.6 (C-
1), 53.0 (C-16), 55.3 (C-3), 113.9 (C-14), 116.8 (C-8), 128.9 (C-13), 130.2 (C-12), 158.4 
(C-9), 158.8 (C-15), 161.8 (C-10), 169.7 (C-2), 171.7 (C-5) ppm; ESI MS (m/z): 957 
[2×M+H]
+
, 501, 479 [M+H]
+
, 391, 234, 199, 163; HRMS (ESI): calc. for C26H31O5N4
+
 
([MH]+): 479.2289, found: 479.2284; IR (thin film, cm–1): 3417 (br), 3006, 2954, 2836, 
1743, 1658, 1607, 1539, 1511, 1436, 1418, 1361, 1110, 1034; Enantiomeric excess (ee): 
99 % [HPLC: ODH column, 25 °C, hexane/i-PrOH: 20/80, 1 mL/min., ret. times: 13.2 
min. (minor), 24.2 min. (major)]; Optical rotation: [α]D = +120° (c = 0.1, CH2Cl2). 
 
 
(R)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)propan-
oate (63) 
 
(Z)-Methyl-2-acetamido-3-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)acrylate (61) 
(0.15 g, 0.32 mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate (0.005 g, 
0.013 mmol, 4 mol%) and (R,R)-Me-DUPHOS (0.008 g, 0.0025 mmol, 8 mol%) were 
added in a steel autoclave. After purging with H2 two times degassed MeOH (20 mL) was 
inserted and the reaction mixture was degassed again for three times. The reaction was 
stirred at room temperature with 38 bar of H2 for 24 h and stopped via release of H2 
pressure. After filtration through Celite the crude oil was purified via column 
chromatography (hexane/ethyl acetate, 1:2, Rf = 0.29) to give (S)-methyl-2-acetamido-3-
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(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)propanoate 63 (0.14 g, 91%) as a 
colourless solid. (m.p.: 66 - 68 °C). 
 
 
63 
 
1
H NMR (400 MHz, CDCl3):  = 2.04 (3H, s, H-6), 2.90-3.08 (2H, m, H-7), 3.78 (3H, s, 
H-1), 3.79 (6H, s, H-16), 4.74 (4H, s, H-11), 4.81-4.87 (1H, m, H-3), 6.09 (1H, d,
 
J = 7.4 
Hz, H-4), 6.83 (4H, d,
 3
JHH = 8.7 Hz, H-14), 7.14 (4H, d,
 3
JHH = 8.7 Hz, H-13), 8.09 (2H, s, 
H-9) ppm; 
13
C NMR (125 MHz, CDCl3):  = 23.2 (C-6), 31.8 (C-7), 48.1 (C-11), 52.6 (C-
1), 53.0 (C-16), 55.3 (C-3), 113.9 (C-14), 116.8 (C-8), 128.9 (C-13), 130.2 (C-12), 158.4 
(C-9), 158.8 (C-15), 161.8 (C-10), 169.7 (C-2), 171.7 (C-5) ppm; ESI MS (m/z): 957 
[2×M+H]
+
, 501, 479 [M+H]
+
, 391, 234, 199, 163; HRMS (ESI): calc. for C26H31O5N4
+
 
([MH]+): 479.2289, found: 479.2283; IR (thin film, cm–1): 3417 (br), 3006, 2954, 2836, 
1743, 1658, 1607, 1539, 1511, 1436, 1418, 1361, 1110, 1034; Enantiomeric excess (ee): 
99 % [HPLC: ODH column, 25 °C, hexane/i-PrOH: 20/80, 1 mL/min., ret. times: 13.3 
min. (major), 24.2 min. (minor)]; Optical rotation: [α]D = -120° (c = 0.1, CH2Cl2). 
 
 
Diethyl-2-(tert-butoxycarbonylimino)malonate (74) 
 
Under nitrogen atmosphere N-Boc-triphenyliminophophorane 81 (11.84 g, 31.38 mmol, 
1.1 eq.) was dissolved in dry THF (60 mL) and diethylmesoxalate (4.94 g, 28.36 mmol, 
1.0 eq.) was added at room temperature. The THF was removed under reduced pressure 
after 16 h at 80 °C and a colourless solid was obtained. Cooled dry diethyl ether (20 mL) 
was added and the solid (PPh3O) was filtered of by washing with cooled dry diethyl ether. 
The solvent was removed under reduced pressure and the light yellow oil was purified by 
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kugelrohr distillation to give diethyl-2-(tert-butoxycarbonylimino)malonate 74 (9.05 g, 
50%) as a colourless oil. 
 
 
74 
 
1
H NMR (500 MHz, CDCl3):  = 1.49 (6H, m, H-7), 1.70 (9H, s, H-1), 4.52 (4H, m, H-6) 
ppm; 
13
C NMR (125 MHz, CDCl3):  = 14.6, 28.6, 63.8, 64.0, 85.3, 152.3, 158.7, 158.9 
ppm. 
 
 
tert-Butyl di-(ethoxycarbonyl)(2-(dibenzylamino)pyrimidin-5-yl)methylcarbamate 
(79) 
 
Under nitrogen atmosphere 25 (0.8 g, 2.0 mmol, 1.0 eq.) was dissolved in THF (10 mL) 
and i-PrMgCl (1.1 mL, 2.2 mmol, 1.1 eq., 2M in THF) was added via syringe at room 
temperature. A solution of 74 (0.44 g, 2.0 mmol, 1.0 eq.) in THF (1 mL) was added after 
5 h and the reaction solution was stirred further for the next 16 hours. Sat. aq. NH4Cl 
(4 mL) was added and the water phase was washed with ethyl acetate (2x5 mL). The 
combined organic phase was washed with brine (10 mL), dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product was purified by column 
chromatography (first column hexane/ethyl acetate, 10:1, Rf = 0.12; second column 
dichloromethane, Rf = 0.16) to give tert-butyl di-(ethoxycarbonyl)(2-(dibenzylamino)-
pyrimidin-5-yl)methylcarbamate 79 (0.22g, 20%) as a yellow oil. 
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79 
 
1
H NMR (500 MHz, CDCl3):  = 1.27 (6H, t, 
3
JHH = 7.1 Hz, H-12), 3.57 (9H, s, H-16), 
4.16-4.39 (4H, m, H-11), 4.66 (4H, s, H-4), 6.29 (1H, s, H-13), 7.17-7.35 (10H, m, H-6, 
H-7, H-8), 8.62 (2H, s, H-2) ppm; 
13
C NMR (125 MHz, CDCl3):  = 14.0 (C-12), 28.3 (C-
16), 49.0 (C-4), 63.2 (C-11), 65.9 (C-9), 81.0 (C-15), 116.1 (C-1), 127.1 (C-8), 127.7 (C-
6), 128.6 (C-7), 138.0 (C-5), 154.0 (C14), 157.6 (C-2), 162.0 (C-3), 167.1 (C-10) ppm; 
ESI MS (m/z): 549 [M+H]
+
, 477, 475, 457, 434, 401, 375, 362, 276, 270, 184, 176, 106, 
91, 78, 58, 44; HRMS (ESI): calc. for C30H37O6N4
+
 ([MH]+): 549.2708, found: 
549.2709.IR (KBr disk, cm
–1
): 3684, 3420, 2983, 1741, 1715, 1570, 1515, 1485, 1454, 
1426, 1394, 1368, 1257, 1161, 1025. 
 
 
N-Boc-triphenyliminophosphorane (81) (Armstrong, Alan; Org. Lett.) 
 
A solution of tert-butylcarbazate (80) (5.00 g, 37.8 mmol, 1.0 eq.) in acetic acid (10 mL) 
and water (20 mL) was cooled to 0 °C. NaNO2 (2.87 g, 41.6 mmol, 1.1 eq.) was added in 
small portions and the reaction mixture was then stirred for 25 min. at 0 °C. The produced 
azide was extracted with diethylether (2x30 mL) and the combined organic phase was 
washed with water (60 mL), sat. aq. NaHCO3 (40 mL, quickly) and brine (40 mL). This 
ether solution was used directly for the second step. PPh3 (9.92 g, 37.8 mmol, 1.0 eq.) was 
added in small portions (strong N2 evolution) at 0 °C. After 1.5 h at room temperature the 
precipitated product was filtered and dried. N-Boc-triphenyliminophophorane 81 (11.8 g, 
83%) was obtained as colourless solid. 
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81 
 
1
H NMR (250 MHz, CDCl3):  = 3.39 (9H, s, H-1), 7.47-7.68 (8H, m, H-5, H-7), 7.72-
7.75 (6H, m, H-6) ppm; 
13
C NMR (125 MHz, CDCl3):  = 28.3 (C-1), 77.8 (C-2), 128.5 
(C-6, 
3
JCP = 12 Hz), 128.6 (C-4, 
1
JCP = 101 Hz), 132.1 (C-7, 
4
JCP = 3 Hz), 133.1 (C-5, 
2
JCP 
= 10 Hz), 161.2 (C-3) ppm. 
 
 
Diethyl-2-amino-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate (82) 
 
Diethyl-2-(tert-butoxycarbonylamino)-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate (79) 
(0.15 g, 0.27 mmol) was dissolved in 10% TFA in DCM (10 mL) at room temperature for 
4 h. The yellow solution was then washed with sat. aq. NaHCO3 (2  20 mL) to remove 
the TFA. The solvent was removed under reduced pressure to give diethyl-2-amino-2-(2-
(dibenzylamino)pyrimidin-5-yl)malonate 82 (1.12 g, 97%) as a yellow oil. Rf = 0.41 
(dichloromethane plus 1% TEA). 
 
 
82 
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1
H NMR (500 MHz, CDCl3):  = 1.23 (6H, t, 
3
JHH = 7 Hz, H-12), 4.21 (4H, m, H-11), 
4.80 (4H, s, H-4), 7.09 – 7.32 (10H, m, H-6, H-7, H-8), 8.49 (2H, s, H-2) ppm; 13C 
NMR (125 MHz, acetone-d6):  = 15.3 (C-12), 50.9 (C-4), 63.8 (C-11), 68.0 (C-9), 119.0 
(C-1), 121.8 (C-1), 128.8 (C-8), 129.4 (C-6), 130.2 (C-7), 140.4 (C-5), 159.2 (C-2), 163.7 
(C-3), 172.2 (C-10) ppm; EI MS (m/z): 448 [M]
+
, 375, 357, 284, 209, 91; HRMS (ESI): 
calc. for C25H29O4N4
+
 ([MH]+): 449.2183, found: 449.2188; IR (thin film, cm–1): 1737, 
1602, 1515, 1453, 1426, 1364, 1028. 
 
 
Diethyl-2-acetamido-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate (84) 
 
Triethylamine (0.13 mL, 0.93 mmol, 4.0 eq.) was added into a solution of diethyl-2-
amino-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate 82 (0.10 g, 0.22 mmol, 1.0 eq.) in 
acetic anhydride (5 mL). The yellow solution was stirred at room temperature for 4 h until 
the conversion was complete (TLC control). The reaction was quenched with water 
(20 mL). Ethyl acetate (15 mL) was added and the org. phase was washed with water 
(2 × 10 mL), dried over Na2SO4 and filtered. The solvent was removed under reduced 
pressure to yield diethyl-2-acetamido-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate 84 
(0.12 g, 99%) as a brown oil. Rf = 0.20 (dichloromethane). 
 
 
84 
 
1
H NMR (400 MHz, acetone-d6):  = 1.08 (6H, t, 
3
JHH = 7 Hz, H-12), 1.98 (3H, s, H-15), 
4.22 (4H, m, H-11), 4.85 (4H, s, H-4), 7.03 – 7.26 (10H, m, H-6, H-7, H-8), 7.87 (1-H, s, 
H-13), 8.41 (2H, s, H-2) ppm; 
13
C NMR (125 MHz, acetone-d6):  = 15.2 (C-12), 23.5 (C-
15), 51.0 (C-4), 64.4 (C-11), 67.8 (C-9), 119.0 (C-1), 128.8 (C-8), 129.4 (C-6), 130.3 (C-
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7), 140.3 (C-5), 159.4 (C-2), 163.6 (C-3), 168.6 (C-14), 171.0 (C-10) ppm; CI MS (m/z): 
491 [MH]+, 434, 419, 362, 276, 106, 77; HRMS (ESI): calc. for C27H31O5N4
+
 ([MH]+): 
491.2289, found: 491.2287; IR (thin film, cm
–1
): 3680, 3428, 2982, 1740, 1608, 1515, 
1454, 1426, 1368, 1255, 1165, 1027. 
 
 
Ethyl-2-acetamido-2-(2-(dibenzylamino)pyrimidin-5-yl)propanoate (85) 
 
Diethyl-2-acetamido-2-(2-(dibenzylamino)pyrimidin-5-yl)malonate 84 (0.13 g, 
0.26 mmol, 1.0 eq.) and LiBr (0.045 g, 0.52 mmol, 2.0 eq.) were dissolved in DMF 
(10 mL) and one drop of water. After stirring at 130 C for 19 h the reaction was quenched 
with water (20 mL) and ethyl acetate (15 mL) was added. The organic layer was washed 
with brine (15 mL) and the combined water layer was then washed with ethyl acetate 
(15 mL). The combined organic phase was dried over Na2SO4, filtered and the solvent was 
removed under reduced pressure. The crude solid was purified via column 
chromatography (hexane/ethyl acetate, 1:1, Rf = 0.35) to give ethyl-2-acetamido-2-(2-
(dibenzylamino)-pyrimidin-5-yl)propanoate 85 (0.06 g, 56%) as a light yellow oil. 
 
 
85 
 
1
H NMR (500 MHz, acetone-d6):  = 1.21 (3H, t, 
3
JHH = 7 Hz, H-12), 1.96 (3H, s, H-16), 
4.18 (2H, m, H-11), 4.86 (4H, 2 × d, JHH = 15 Hz, 4 Hz, H-4), 5.39 (1-H, d,
 3
JHH = 7 Hz, 
H-13), 7.22 – 7.34 (10H, m, H-6, H-7, H-8), 7.86 (1-H, bd, H-14), 8.41 (2H, s, H-2) ppm; 
13
C NMR (125 MHz, acetone-d6):  = 15.4 (C-12), 23.5 (C-16), 51.1 (C-4), 54.3 (C-11), 
63.1 (C-9), 121.1 (C-1), 128.9 (C-8), 129.4 (C-6), 130.3 (C-7), 140.4 (C-5), 159.2 (C-2), 
163.9 (C-3), 170.9 (C-10), 172.1 (C-15) ppm; EI MS (m/z): 418 [M]
+
, 345, 372, 303, 281, 
253, 211, 91; HRMS (ESI): calc. for C24H27O3N4
+
 ([MH]+): 419.2078, found: 419.2078; 
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IR (thin film, cm
–1
): 3682, 3428, 2980, 1741, 1608, 1514, 1455, 1426, 1367, 1254, 1165, 
1025. 
 
 
N-Acetyl-triphenyliminophophorane (87) 
 
A mixture of sodium azide (0.85 g, 13.0 mmol, 1.3 eq.) in acetone (50 mL) was cooled to 
0 °C. Acetylchloride (0.71 mL, 10.0 mmol, 1.0 eq.) was added via syringe followed by 
triphenylphosphine (2.62 g, 10.0 mmol, 1.0 eq.) which was added in small portions. The 
reaction was stirred at room temperature for 40 min. Acetone was removed under reduced 
pressure and dichloromethane (20 mL) was added to the colourless solid. The salts were 
filtered off and the product was precipitated by adding diethyl ether (six drops) to the 
solution. The colourless solid was filtered off and dried to give N-acetyl-
triphenyliminophophorane 87 (2.41 g, 76%). 
 
 
87 
 
1
H NMR (500 MHz, CDCl3):  = 2.26 (3H, d, 
3
JHH = 2.9 Hz, H-1), 7.43-7.49 (6H, m, H-
5), 7.52-7.58 (3H, m, H-6), 7.70-7.77 (6H, m, H-4) ppm; 
13
C NMR (125 MHz, 
CDCl3):  = 27.5 and 27.6 (J = 19.9 Hz, C-1), 128.3 and 128.4 (J = 7.0 Hz, C-3), 128.6 
and 128.7 (J = 12.3 Hz, C-5), 132.2 (C-6), 133.0 and 133.1 (J = 9.9 Hz, C-4), 182.8 (C-2) 
ppm. 
 
 
Diethyl-2-(acetylimino)malonate (88) 
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Under nitrogen atmosphere N-acetyl-triphenyliminophophorane 87 (3.80 g, 11.9 mmol, 
1.1 eq.) was dissolved in dry THF (40 mL) and diethylmesoxalate (1.63 mL, 10.7 mmol, 
1.0 eq.) was added at room temperature. The THF was removed under reduced pressure 
after refluxing for 17 h at 80 °C and a yellow solid was obtained. Cooled dry diethyl ether 
(6 mL) was added and the solid (PPh3O) was filtered of by washing with cooled dry 
diethyl ether. The solvent was removed under reduced pressure and the light yellow oil 
was purified by kugelrohr distillation to give diethyl-2-(acetylimino)malonate 88 (1.18 g, 
51%) as a colourless oil. 
 
 
88 
 
1
H NMR (500 MHz, CDCl3):  = 1.13-1.32 (6H, m, H-6), 2.03 (3H, s, H-1), 4.12-4.33 
(4H, m, H-5) ppm; 
13
C NMR (125 MHz, CDCl3):  = 13.2 (C-6), 22.3 (C-1), 62.1 (C-5), 
162.6 (C-3), 165.0 (C-4), 169.3 (C-2) ppm. 
 
 
2-(5-Iodopyrimidin-2-yl)isoindoline-1,3-dione (90) 
 
The reaction was done in a microwave reactor without solvent. 2-Amino-5-iodopyrimidine 
(0.028 g, 0.13 mmol, 1.0 eq.) and phthalic anhydride (0.029 g, 0.20 mmol, 1.5 eq.) were 
added to the microwave tube and the tube was sealed. The reaction was carried out at 300 
watts, 220 °C for 5 minutes. Chloroform (5 mL) and sat. aq. NaHCO3 solution (5 mL) 
were added to the tube and the org. layer was separated and dried over MgSO4. The crude 
product was purified via column chromatography (DCM/ethyl acetate, 50:1, Rf = 0.50) to 
give 2-(5-iodopyrimidin-2-yl)isoindoline-1,3-dione (90) (0.028 g, 62%) as colourless 
solid. (m.p.: 134-136 °C). 
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90 
 
1
H NMR (500 MHz, CDCl3):  = 7.84 (2H, m, H-6), 8.00 (2H, m, H-7), 9.09 (2H, s, H-2) 
ppm; 
13
C NMR (125 MHz, CDCl3):  = 76.2 (C-1), 124.3 (C-6), 131.6 (C-5), 134.9 (C-7), 
163.2 (C-3), 164.5 (C-2), 165.4 (C-4) ppm; ESI MS (m/z): 703 [2×M+H]
+
, 374, 369, 352 
[M+H]
+
, 282, 217, 163, 150; HRMS (ESI): calc. for C12H6IN3O2
+
 ([M+H]
+
): 351.9577, 
found: 351.9580; IR (thin film, cm
–1
): 3033, 2954, 2834, 1784, 1756, 1720, 1537, 1465, 
1418, 1378, 1363, 1260, 1098, 1082, 1008. 
 
 
N, N-Di-tert-butoxycarbonyl-2-aminopyrimidin-5-ol (91) 
 
N, N-Di-tert-butoxycarbonyl-5-iodopyrimidin-2-amine 32 (0.10 g, 0.24 mmol, 1.0 eq.), 
bis(pinacolatodiboron) (0.18 g, 0.71 mmol, 3.0 eq.), potassium acetate (0.07 g, 0.71 mmol, 
3.0 eq.) and palladium(II)acetate (0.003 g, 0.013 mmol, 5.6 mol%) were mixed with DMF 
(2 mL) and heated up to 85 °C. After 6 ½ h the reaction was not finished and 
bis(pinacolatodiboron) (0.11 g, 0.43 mmol, 1.8 eq.) and palladium(II)acetate (0.002 g, 
0.009 mmol, 3.8 mol%) were added. The reaction was quenched after 24 hours with water 
(2 mL) and extracted with ethyl acetate (3 × 3 mL). The combined org. layer was washed 
with brine (2 mL) and water (2 mL). The org. layer was concentrated and dried in vacuo 
and THF (2 mL) and water (2 mL) were added to the yellow oil. Sodium perborate 
tetrahydrate (0.11 g, 0.73 mmol, 3.0 eq.) was added and the mixture was stirred for 24 h at 
room temperature. Sat. aq. NH4Cl solution (5 mL) was added and the solution extracted 
with ethyl acetate (6 mL). The org. layer was dried over MgSO4, filtered and the solvent 
was removed under reduced pressure. The crude product was purified via column 
chromatography (ethyl acetate/chloroform, 30:70, Rf = 0.16) to give N, N-di-tert-
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butoxycarbonyl-2-amino-pyrimidin-5-ol 91 (0.05 g, 67%) as a light yellow solid. (m.p.: 
133 - 135 °C). 
 
 
91 
 
1
H NMR (500 MHz, CDCl3):  = 1.41 (18H, s, H-7), 8.32 (2H, s, H-3), ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 27.8 (C-7), 83.9 (C-6), 146.0 (C-3), 150.0 (C-2), 150.5 (C-
4), 151.2 (C-5) ppm; ESI MS (m/z): 645 [2×M+Na]
+
, 623 [2×M+H]
+
, 487, 433, 380, 334 
[M+Na]
+
, 312 [M+H]
+
, 212, 176; HRMS (ESI): calc. for C14H21O5N3Na
+
 ([MNa]+): 
334.1373, found: 334.1377; IR (KBr disk, cm
–1
): 2981, 2851 (br), 2704 (br), 2587 (br), 
1757, 1735, 1723, 1568, 1439, 1397, 1375, 1292, 1260, 1149, 1107, 1061, 1030. 
 
 
 (S)-Methyl-2-(tert-butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-
yl)propan-oate (92) 
 
(Z)-Methyl-2-(tert-butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)-acrylate 
(38) (0.02 g, 0.04 mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetra-fluoroborate 
(0.008 g, 0.02 mmol, 4.5 mol%) and (S,S)-Me-DUPHOS (0.005 g, 0.015 mmol, 3.5 mol%) 
were added to a steel autoclave. After purging three times with H2, degassed MeOH 
(20 mL) was inserted and the reaction mixture was degassed again three times. The 
reaction was stirred at room temperature with 35 bar of H2 for three days and stopped via 
release of H2 pressure. After filtration through Celite the proton NMR of the crude oil 
showed 67% product and 33% starting material. Because the compound mixture is not 
separable via column chromatography the crude oil was purified by preparative TLC 
(DCM/methanol, 200:1, Rf = 0.25) to give (S)-methyl-2-(tert-butoxy-carbonylamino)-3-(2-
(dibenzyl-amino)pyrimi-din-5-yl)propanoate 92 (0.0012 g, 7%) as a colourless solid. 
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92 
 
1
H NMR (500 MHz, CDCl3):  = 1.25 (9H, s, H-7), 2.77-2.95 (2H, m, H-8), 3.69 (3H, s, 
H-1), 4.49 (1H, m, H3), 4.78 (4H, s, H-12), 5.03 (1H, d,
 3
JHH = 7.3 Hz, H-4), 7.13-7.26 
(10H, m, H-14, H-15, H-16), 8.07 (2H, s, H-10) ppm; 
13
C NMR (125 MHz, 
CDCl3):  = 28.3 (C-7), 32.1 (C-8), 49.1 (C-12), 53.1 (C-1), 55.0 (C-3), 116.8 (C-9), 127.0 
(C-16), 127.6 (C-14), 128.5 (C-15), 138.1 (C-13), 158.8 (C-10), 162.5 (C-11), 166.5 (C-5), 
171.7 (C-2) ppm; ESI MS (m/z): 478 [M+H]
+
, 387, 377, 197; IR (thin film, cm
–1
): 3374, 
3086, 3062, 3026, 2979, 2930, 1744, 1714, 1606, 1541, 1509, 1453, 1435, 1403, 1365, 
1253, 1227, 1165, 1057, 1028. 
 
 
(R)-Methyl-2-(tert-butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)-
propanoate (93) 
 
(Z)-Methyl-2-(tert-butoxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)acrylate 
(38) (0.02 g, 0.04 mmol, 1.0 eq.), bis(1,5-cyclooctadiene)rhodium(I)tetra-fluoroborate 
(0.008 g, 0.02 mmol, 4.5 mol%) and (R,R)-Me-DUPHOS (0.005 g, 0.015 mmol, 
3.5 mol%) were added to a steel autoclave. After purging three times with H2, degassed 
MeOH (20 mL) was inserted and the reaction mixture was degassed again three times. The 
reaction was stirred at room temperature with 35 bar of H2 for two days and stopped via 
release of H2 pressure. After filtration through Celite the proton NMR of the crude oil 
showed 70% product and 30% starting material. Because the compound mixture is not 
separable via column chromatography the crude oil was purified by preparative TLC 
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(DCM/methanol, 200:1, Rf = 0.25) to give (R)-methyl-2-(tert-butoxy-carbonylamino)-3-
(2-(dibenzyl-amino)pyrimi-din-5-yl)propanoate 93 (0.0014 g, 8%) as a colourless solid. 
 
 
93 
 
1
H NMR (500 MHz, CDCl3):  = 1.25 (9H, s, H-7), 2.77-2.95 (2H, m, H-8), 3.69 (3H, s, 
H-1), 4.49 (1H, m, H3), 4.78 (4H, s, H-12), 5.03 (1H, d,
 3
JHH = 7.3 Hz, H-4), 7.13-7.26 
(10H, m, H-14, H-15, H-16), 8.07 (2H, s, H-10) ppm; 
13
C NMR (125 MHz, 
CDCl3):  = 28.3 (C-7), 32.1 (C-8), 49.1 (C-12), 53.1 (C-1), 55.0 (C-3), 116.8 (C-9), 127.0 
(C-16), 127.6 (C-14), 128.5 (C-15), 138.1 (C-13), 158.8 (C-10), 162.5 (C-11), 166.5 (C-5), 
171.7 (C-2) ppm; ESI MS (m/z): 478 [M+H]
+
, 387, 377, 197; IR (thin film, cm
–1
): 3374, 
3086, 3062, 3026, 2979, 2930, 1744, 1714, 1606, 1541, 1509, 1453, 1435, 1403, 1365, 
1253, 1227, 1165, 1057, 1028. 
 
 
(S)-Methyl-2-amino-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoate (94) 
 
(S)-Methyl-2-acetamido-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoate (0.18 g, 
0.43 mmol, 1.0 eq.) was dissolved in methanol (4 mL). Thionyl chloride (0.15 mL, 
2.07 mmol, 4.8 eq.) was slowly added at 0 °C and the solution was then refluxed at 80 °C 
for 18 h. Methanol was removed under reduced pressure and ethyl acetate (20 mL) and sat. 
aq. NaHCO3 solution (20 mL) were added. The water layer was washed with ethyl acetate 
(2 × 15 mL) and the combined org. layer was then dried over MgSO4 and filtered. The 
crude product was purified by column chromatography (hexane/ethyl acetate, 1:8 with 
0.1% TEA, Rf = 0.26) to give (S)-methyl-2-amino-3-(2-(dibenzylamino)pyrimidin-5-
yl)propanoate 94 (0.12 g, 76%) as light yellow oil. 
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94 
 
1
H NMR (400 MHz, CDCl3):  = 2.63-2.86 (2H, m, H-5), 3.56-3.62 (1H, m, H-3), 3.67 
(3H, s, H-1), 4.71-4.85 (4H, dd, J = 15.7 Hz, 17.6 Hz, H-9), 7.10-7.27 (10H, m, H-11, H-
12, H-13), 8.15 (2H, s, H-7) ppm; 
13
C NMR (125 MHz, CDCl3):  = 34.7 (C-5), 49.0 (C-
9), 52.2 (C-1), 55.3 (C-3), 117.9 (C-6), 127.0 (C-13), 127.5 (C-11), 128.4 (C-12), 138.2 
(C-10), 158.5 (C-7), 161.7 (C-8), 175.2 (C-2) ppm; ESI MS (m/z): 399 [M+Na]
+
, 377 
[M+H]
+
, 360, 279; HRMS (ESI): calc. for C22H25O2N4
+
 ([MH]+): 377.1972, found: 
377.1971; IR (thin film, cm
–1
): 3383 (br), 3086, 3062, 3027, 2951, 2922, 1739, 1674, 
1605, 1540, 1510, 1453, 1424, 1402, 1362, 1258, 1229, 1175, 1028. 
 
 
(S)-2-(Benzyloxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoic acid 
(95) 
 
Under nitrogen atmosphere (S)-1-carboxy-2-(2-(dibenzylamino)pyrimidin-5-yl)ethan-
aminium chloride (46) (0.18 g, 0.45 mmol, 1.0 eq.), N-hydroxybenzotriazol (0.07 g, 
0.52 mmol, 1.1 eq.) and benzyl chloroformate (0.09 ml, 0.63 mmol, 1.4 eq.) were mixed 
with dry DCM (6 ml). Triethylamine (0.44 ml, 3.17 mmol, 7.0 eq.) was added and the 
light yellow solution stirred at room temperature for 4 h. 1 M HCl (6 ml) was added and 
the org. layer dried over MgSO4. The crude product was purified via column 
chromatography (hexane/ethyl acetate plus 0.1% acetic acid, 1:1, Rf = 0.26) to give (S)-2-
(benzyloxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoic acid 95 
(0.16 g, 72%) as colourless solid. (m.p.: 164 – 165 °C). 
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95 
 
1
H NMR (500 MHz, DMSO-d6, 80 °C):  = 2.69-2.98 (2H, m, H-11), 4.15-4.22 (1H, m, 
H-3), 4.81 (4H, s, H-15), 5.00 (2H, s, H-6), 7.17-7.35 (15H, m, H-Ar), 7.42 (1H, br s, H-
4), 8.27 (2H, s, H-13) ppm; 
13
C NMR (125 MHz, CDCl3):  = 31.5 (C-11), 49.8 (C-15), 
54.4 (C-3), 67.1 (C-6), 117.3 (C-12), 2×127.2 (C-Ar), 128.1 (C-Ar), 128.3 (C-Ar), 128.6 
(C-Ar), 136.2 (C-7), 137.2 (C-16), 155.6 (C-5), 158.5 (C-13), 160.4 (C-14), 172.5 (C-2) 
ppm; ESI MS (m/z): 519 [M+Na]
+
, 497 [M+H]
+
, 453, 391, 199; HRMS (ESI): calc. for 
C29H29O4N4
+
 ([M+H]
+
): 497.2183, found: 497.2176; IR (thin film, cm
–1
): 3419 (br), 3029, 
2925, 1713, 1607, 1542, 1506, 1453, 1423, 1362, 1260, 1218, 1057, 1028. 
 
 
(S)-Methyl-2-(benzyloxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-
yl)propanoate (96) 
 
Iodomethane (0.024 mL, 0.39 mmol, 1.5 eq.) was added drop wise to a mixture of (S)-2-
(benzyloxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)propanoic acid (95) 
(0.128 g, 0.26 mmol, 1.0 eq.) and potassium carbonate (0.072 g, 0.52 mmol, 2.0 eq.) in 
DMF (5 mL). After stirring for 18 h at room temperature the reaction mixture was washed 
with water (2 × 8 mL). The org. layer was washed with sat. aq. NaHCO3 solution 
(2 × 8 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified via column chromatography (hexane/ethyl acetate, 2:1, Rf = 0.42) to give (S)-
methyl 2-(benzyloxycarbonylamino)-3-(2-(dibenzylamino)pyrimidin-5-yl)propan-oate 96 
(0.082 g, 62%) as colourless oil. 
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96 
 
1
H NMR (400 MHz, CDCl3):  = 2.76-2.96 (2H, m, H-11), 3.64 (3H, s, H-1), 4.46-4.56 
(1H, m, H-3), 4.75 (4H, dd, J = 16 Hz, 2 Hz, H-15), 5.00 (2H, dd, J = 12 Hz, 6 Hz, H-6), 
5.39 (1H, d, J = 7.7 Hz, H-4), 7.00-7.31 (15H, m, H-Ar), 8.02 (2H, s, H-13) ppm; 
13
C 
NMR (125 MHz, CDCl3):  = 32.1 (C-11), 49.0 (C-15), 52.4 (C-1), 54.5 (C-3), 67.0 (C-6), 
116.7 (C-12), 126.9 (C-Ar), 127.4 (C-Ar), 128.0 (C-Ar), 128.1 (C-Ar), 128.4 (C-Ar), 
128.5 (C-Ar), 136.0 (C-7), 138.0 (C-16), 155.5 (C-5), 158.3 (C-13), 161.7 (C-14), 171.4 
(C-2) ppm; ESI MS (m/z): 533 [M+Na]
+
, 511 [M+H]
+
, 419, 391, 327; HRMS (ESI): calc. 
for C30H31O4N4
+
 ([M+H]
+
): 511.2340, found: 511.2335; IR (thin film, cm
–1
): 3341 (br), 
3087, 3063, 3029, 2952, 1951, 1722, 1606, 1540, 1506, 1453, 1435, 1403, 1362, 1258, 
1217, 1059, 1028. 
 
 
General procedure for Fmoc-peptide synthesis 
 
Resin preparation: 
The resin was added to a plastic syringe with a glass sinter base. The outlet of the syringe 
was connected to a membrane pump via a collecting tank. NMP was added in order to 
swell the resin and left for at least 2 h before the solvent was removed by vacuum 
filtration. 
 
Fmoc-Deprotecting / Coupling cycle: 
For Fmoc removal, a 50% piperidine/NMP (v/v) solution was added and stirred for 10 
min. at room temperature. The solvent was removed by vacuum filtration and this step was 
repeated. The resin was washed four times with NMP. A solution of Fmoc protected 
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amino acid (4 eq.; 2 eq. for amino acid with biotinyl tag), PyBOP (4 eq.) and DIEA (4 eq.) 
in NMP was added and stirred for 45 min. at room temperature. The solvent was removed 
by vacuum filtration and the coupling step was repeated. The resin was then washed four 
times with NMP. 
The deprotecting / coupling cycle was repeated for each of the subsequent amino acids. 
 
Removal of the N-terminal Fmoc group and drying the peptide resin: 
A 50% piperidine/NMP (v/v) solution was added and stirred for 10 min. at room 
temperature. The solvent was removed by vacuum filtration and this step was repeated. 
The resin was washed three times with NMP, three times with chloroform, three times 
with methanol and three times with diethyl ether. 
 
Cleavage of the peptide from resin and deprotection of side chains: 
Mixture of thioanisol (5.0%), ethanedithiol (2.5%), m-cresol (5.0%), water (5.0%) and 
TFA (82.5%) was added to the peptide resin and left for 6 h at room temperature. The 
filtrate was collected and the resin washed with TFA. Diethyl ether (40 mL) was added to 
a tube containing the combined filtrate and washing to precipitate the peptide. The tube 
was centrifuged (5 min., 4 °C, spin 2800 rpm) and the solution decanted from the peptide 
pellet. The peptide pellet was then washed with diethyl ether (40 mL) and centrifuged for 
three more times. The peptide was dried under nitrogen flow. 
 
 
Positive-Peptide ((H2N-RKRKGGG)2KGGGX-NH2) 
 
General procedure was used with Rink Amide MBHA resin (100-200 μm, 0.34 mmol/g, 
0.06 g). The amino acids up to the two times Fmoc protected Lys (to creating the branch) 
were added with just one coupling cycle of 45 min. The following amino acids were added 
with 8 eq. of Fmoc protected amino acid, PyBOP and DIEA. Peptide identity was 
confirmed by MALDI-ToF mass spectrometry. 
MALDI-ToF: calculated M+H: 2354; found M+H: 2354. 
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Negative-Peptide ((H2N-EEEEGGG)2KGGGX-NH2) 
  
General procedure was used with Rink Amide MBHA resin (100-200 μm, 0.34 mmol/g, 
0.06 g). The amino acids up to the two times Fmoc protected Lys (to creating the branch) 
were added with just one coupling cycle of 45 min. The following amino acids were added 
with 8 eq. of Fmoc protected amino acid, PyBOP and DIEA. Peptide identity was 
confirmed by MALDI-ToF mass spectrometry. 
MALDI-ToF: calculated M+K: 2288, M+Na: 2271; found major peak M+K: 2288, minor 
peak M+Na: 2271. 
 
 
Peptide Library Fragment (Fmoc-CKGGX-resin) 
General procedure was used with Polystyrene AMRAM resin (500-560 μm, 0.53 mmol/g, 
0.0468 g). The peptide was cleaved off four test beads to confirm the identity of the 
peptide by MALDI-ToF mass spectrometry. 
MALDI-ToF: calculated M+H: 920; found M+H: 920. 
 
 
Peptide Library 
Half of the amount of the prior prepared Peptide Library Fragment was used. The library 
was synthesised using the general procedure in combination with the split and recombine 
strategy. The beads were split in four pools and Fmoc protected Phe, Ile, Thr or Tyr was 
coupled to the peptide. The beads were then all recombined for the Fmoc-deprotection. 
The beads were split in two pools to couple Fmoc protected Lys or Arg and recombined 
for the Fmoc-deprotection. The next two Fmoc protected amino acids D-Cys and Ala were 
added to all beads in one pool. After splitting the beads in two pools Fmoc protected Arg 
or Ser was coupled to the peptide and the beads were recombined for the deprotecting 
step. The beads were split again in four pools and Fmoc protected Leu, Asn, Val or Tyr 
was coupled on. This time the beads were not recombined for the Fmoc-deprotection and 
the addition of the last Fmoc protected amino acid Ala. 96 well plates were used for the 
cleavage of the peptides from the resin. One bead was placed per well because each bead 
contained a different peptide. The cleavage mixture was evaporated under a nitrogen flow 
after the cleavage. Peptide identity can be confirmed by MALDI-ToF mass spectrometry 
as demonstrated on six examples. 
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MALDI-ToF:  
H2N-ANSAC´KTCKGGX-NH2+H: 1596.1614 and H2N-ANSAC´KTCKGGX-NH2+Na: 
1618.1984. 
H2N-AVSAC´KYCKGGX-NH2+H: 1643.2166 and H2N-AVSAC´KYCKGGX-NH2+Na: 
1665.2657. 
H2N-ALSAC´KYCKGGX-NH2+H: 1658.0498 and H2N-ALRAC´RYCKGGX-NH2+Na: 
1679.0645. 
H2N-ALRAC´RYCKGGX-NH2+H: 1754.1547. 
H2N-ALRAC´RTCKGGX-NH2+H: 1692.1808. 
H2N-ANSAC´RFCKGGX-NH2+H: 1670.1793. 
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